5,871 results on '"Division of Allergy and Immunology"'
Search Results
2. Oral immunotherapy for multiple foods in a pediatric allergy clinic setting.
- Author
-
Eapen, Amy A., Lavery, William J., Siddiqui, Jaweriah S., Lierl, Michelle B., Cincinnati Children’s Hospital Medical Center, and Division of Allergy and Immunology
- Published
- 2019
- Full Text
- View/download PDF
3. Transcriptome and Metabolic Analyses of CHAPLE Disease (CHAPLEOMIC)
- Author
-
National Institute of Allergy and Infectious Diseases (NIAID) and Ahmet Ozen, M.D., Prof. Of Pediatrics, Division of Allergy and Immunology
- Published
- 2019
4. Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial
- Author
-
Cengiz Kirmaz, Ozlem Goksel, Münevver Erdinç, Ömür Aydın, Ali Fuat Kalyoncu, Dane Ediger, Arzu Didem Yalcin, Zeynep Ferhan Ozseker, Bilun Gemicioglu, Ahmet Erdogdu, Yavuz Havlucu, Füsun Erdenen, Mustafa Gulec, Papatya Bayrak Degirmenci, Aykut Cilli, Ferda Öner Erkekol, Sibel Atis Nayci, Suna Büyüköztürk, Idilhan Ar, Sami Öztürk, Sacide Rana Işık, Dilşad Mungan, Arzu Yorgancioglu, Department of Chest Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey, Department of Allergy and Immunology, Atatürk Chest Diseases and Thoracic Surgery Research and Training Hospital, Sanatoryum Caddesi, Keçiören/Ankara, TR-06290, Turkey, Division of Allergy and Immunology, Department of Chest Diseases, Faculty of Medicine, Ankara University, Ankara, Turkey, Department of Chest Diseases, Faculty of Medicine, Ege University, Izmir, Turkey, Department of Chest Diseases, Cerrahpaşa School of Medicine, Istanbul University, Istanbul, Turkey, Division of Allergy and Immunology, Department of Chest Diseases, Cerrahpaşa School of Medicine, Istanbul University, Istanbul, Turkey, Department of Allergy and Immunology, Tepecik Research and Training Hospital, Izmir, Turkey, Department of Chest Diseases, Faculty of Medicine, Mersin University, Mersin, Turkey, Department of Chest Diseases, Faculty of Medicine, Akdeniz University, Antalya, Turkey, Department of Internal Medicine, Istanbul Research and Training Hospital, Istanbul, Turkey, Division of Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine, Celal Bayar University, Manisa, Turkey, Division of Allergy and Immunology, Department of Chest Diseases, Faculty of Medicine, Uludaǧ University, Bursa, Turkey, Department of Internal Medicine, Antalya Research and Training Hospital, Antalya, Turkey, Division of Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine, Istanbul University, Istanbul, Turkey, Division of Allergy and Immunology, Department of Internal Medicine, Gulhane Military Medical Academy and Medical School (Haydarpaşa), Istanbul, Turkey, Division of Allergy and Immunology, Department of Internal Medicine, Gulhane Military Medical Academy and Medical School, Ankara, Turkey, Department of Allergy and Immunology, Yedikule Chest Diseases and Thoracic Surgery Research and Training Hospital, Istanbul, Turkey, Division of Allergy and Immunology, Department of Chest Diseases, Faculty of Medicine, Hacettepe University, Ankara, Turkey, Division of Allergy and Immunology, Department of Chest Diseases, Faculty of Medicine, Ege University, Izmir, Turkey, and Medical Department, Novartis Pharmaceuticals, Istanbul, Turkey
- Subjects
Adult ,Male ,Allergy ,medicine.medical_specialty ,Adolescent ,Systemic steroid ,Immunology ,Omalizumab ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Forced Expiratory Volume ,Internal medicine ,medicine ,Humans ,Immunology and Allergy ,Anti-Asthmatic Agents ,030212 general & internal medicine ,Adverse effect ,Aged ,Retrospective Studies ,Asthma ,Aged, 80 and over ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Discontinuation ,Clinical trial ,030228 respiratory system ,Tolerability ,Female ,business ,medicine.drug - Abstract
Background: Omalizumab has demonstrated therapeutic benefits both in controlled clinical trials and real-life studies. However, research concerning the long-term effects and tolerability of omalizumab is needed. The main objective of this study was to evaluate the effectiveness and tolerability of treatment with omalizumab for up to 5 years. Methods: A multicenter, retrospective, chart-based study was carried out to compare documented exacerbations, hospitalizations, systemic steroid requirement, FEV1, and asthma control test (ACT) results during 1 year prior to omalizumab treatment versus at 1, 3, and 5 years of treatment. Adverse events and reasons for discontinuation were also recorded at each time point. Results: Four hundred and sixty-five patients were enrolled in the study. Outcome variables had improved after the 1st year and were sustained after the 3rd and 5th years of treatment with omalizumab. Omalizumab treatment reduced the asthma exacerbation rate by 71.3% (p < 0.001) at 1 year, 64.3% (p < 0.001) at 3 years, and 54.8% (p = 0.002) at 5 years. The hospitalization rate also decreased; by the 5th year of the treatment no patients were hospitalized. ACT results had also improved significantly: 12 (p < 0.001) at 1 year, 12 (p < 0.001) at 3 years, and 12 (p = 0.002) at 5 years. Overall, 12.7% of patients reported adverse events (most of these were mild-to-moderate) and the overall dropout rate was 9.0%. Conclusion: Omalizumab had a significant effect on asthma outcomes and this effect was maintained over 5 years. The drug was found to be generally safe and treatment compliance was good.
- Published
- 2018
5. The Prevalence and Clinical Characteristics of Children With Local Allergic Rhinitis
- Author
-
Orathai Piboonpocanun, Division of allergy and immunology
- Published
- 2018
6. The Natural History of Atopic Disease in Thai Children and Association With Atopic March
- Author
-
Orathai Piboonpocanun, Division of Allergy and Immunology, Department of Pediatrics, Siriraj hospital
- Published
- 2016
7. Involving Community Pharmacies in Improving Asthma Outcomes in an Urban Pediatric Population
- Author
-
National Association of Chain Drug Stores and Stephen J. Teach, MD, MPH, Chief, Division of Allergy and Immunology
- Published
- 2015
8. Immune Responses in Patients Treated With Raltegravir (RAG-1/2)
- Author
-
Merck Sharp & Dohme LLC and Chris Tsoukas, Director, Division of Allergy & CLinical Immunology, MUHC
- Published
- 2015
9. Improving Asthma Care Through Parental Empowerment (PEPAC)
- Author
-
Stephen J. Teach, MD, MPH, Chief, Division of Allergy and Immunology
- Published
- 2014
10. Next-generation ARIA care pathways for rhinitis and asthma: A model for multimorbid chronic diseases
- Author
-
Bousquet, J.J. and Schünemann, H.J. and Togias, A. and Erhola, M. and Hellings, P.W. and Zuberbier, T. and Agache, I. and Ansotegui, I.J. and Anto, J.M. and Bachert, C. and Becker, S. and Bedolla-Barajas, M. and Bewick, M. and Bosnic-Anticevich, S. and Bosse, I. and Boulet, L.P. and Bourrez, J.M. and Brusselle, G. and Chavannes, N. and Costa, E. and Cruz, A.A. and Czarlewski, W. and Fokkens, W.J. and Fonseca, J.A. and Gaga, M. and Haahtela, T. and Illario, M. and Klimek, L. and Kuna, P. and Kvedariene, V. and Le, L.T.T. and Larenas-Linnemann, D. and Laune, D. and Lourenço, O.M. and Menditto, E. and Mullol, J. and Okamoto, Y. and Papadopoulos, N. and Pham-Thi, N. and Picard, R. and Pinnock, H. and Roche, N. and Roller-Wirnsberger, R.E. and Rolland, C. and Samolinski, B. and Sheikh, A. and Toppila-Salmi, S. and Tsiligianni, I. and Valiulis, A. and Valovirta, E. and Vasankari, T. and Ventura, M.-T. and Walker, S. and Williams, S. and Akdis, C.A. and Annesi-Maesano, I. and Arnavielhe, S. and Basagana, X. and Bateman, E. and Bedbrook, A. and Bennoor, K.S. and Benveniste, S. and Bergmann, K.C. and Bialek, S. and Billo, N. and Bindslev-Jensen, C. and Bjermer, L. and Blain, H. and Bonini, M. and Bonniaud, P. and Bouchard, J. and Briedis, V. and Brightling, C.E. and Brozek, J. and Buhl, R. and Buonaiuto, R. and Canonica, G.W. and Cardona, V. and Carriazo, A.M. and Carr, W. and Cartier, C. and Casale, T. and Cecchi, L. and Cepeda Sarabia, A.M. and Chkhartishvili, E. and Chu, D.K. and Cingi, C. and Colgan, E. and De Sousa, J.C. and Courbis, A.L. and Custovic, A. and Cvetkosvki, B. and Damato, G. and Da Silva, J. and Dantas, C. and Dokic, D. and Dauvilliers, Y. and Dedeu, A. and De Feo, G. and Devillier, P. and Di Capua, S. and Dykewickz, M. and Dubakiene, R. and Ebisawa, M. and El-Gamal, Y. and Eller, E. and Emuzyte, R. and Farrell, J. and Fink-Wagner, A. and Fiocchi, A. and Fontaine, J.F. and Gemicioǧlu, B. and Schmid-Grendelmeir, P. and Gamkrelidze, A. and Garcia-Aymerich, J. and Gomez, M. and Diaz, S.G. and Gotua, M. and Guldemond, N.A. and Guzmán, M.-A. and Hajjam, J. and O'Hourihane, J.B. and Humbert, M. and Iaccarino, G. and Ierodiakonou, D. and Ivancevich, J.C. and Joos, G. and Jung, K.-S. and Jutel, M. and Kaidashev, I. and Kalayci, O. and Kardas, P. and Keil, T. and Khaitov, M. and Khaltaev, N. and Kleine-Tebbe, J. and Kowalski, M.L. and Kritikos, V. and Kull, I. and Leonardini, L. and Lieberman, P. and Lipworth, B. and Lodrup Carlsen, K.C. and Loureiro, C.C. and Louis, R. and Mair, A. and Marien, G. and Mahboub, B. and Malva, J. and Manning, P. and De Manuel Keenoy, E. and Marshall, G.D. and Masjedi, M.R. and Maspero, J.F. and Mathieu-Dupas, E. and Matricardi, P.M. and Melén, E. and Melo-Gomes, E. and Meltzer, E.O. and Mercier, J. and Miculinic, N. and Mihaltan, F. and Milenkovic, B. and Moda, G. and Mogica-Martinez, M.-D. and Mohammad, Y. and Montefort, S. and Monti, R. and Morais-Almeida, M. and Mösges, R. and Münter, L. and Muraro, A. and Murray, R. and Naclerio, R. and Napoli, L. and Namazova-Baranova, L. and Neffen, H. and Nekam, K. and Neou, A. and Novellino, E. and Nyembue, D. and O'Hehir, R. and Ohta, K. and Okubo, K. and Onorato, G. and Ouedraogo, S. and Pali-Schöll, I. and Palkonen, S. and Panzner, P. and Park, H.-S. and Pépin, J.-L. and Pereira, A.-M. and Pfaar, O. and Paulino, E. and Phillips, J. and Plavec, D. and Popov, T.A. and Portejoie, F. and Price, D. and Prokopakis, E.P. and Pugin, B. and Raciborski, F. and Rajabian-Söderlund, R. and Reitsma, S. and Rodo, X. and Romano, A. and Rosario, N. and Rottem, M. and Ryan, D. and Salimäki, J. and Sanchez-Borges, M.M. and Sisul, J.-C. and Solé, D. and Somekh, D. and Sooronbaev, T. and Sova, M. and Spranger, O. and Stellato, C. and Stelmach, R. and Ulrik, C.S. and Thibaudon, M. and To, T. and Todo-Bom, A. and Tomazic, P.V. and Valero, A.A. and Valenta, R. and Valentin-Rostan, M. and Van Der Kleij, R. and Vandenplas, O. and Vezzani, G. and Viart, F. and Viegi, G. and Wallace, D. and Wagenmann, M. and Wang, D.Y. and Waserman, S. and Wickman, M. and Williams, D.M. and Wong, G. and Wroczynski, P. and Yiallouros, P.K. and Yorgancioglu, A. and Yusuf, O.M. and Zar, H.J. and Zeng, S. and Zernotti, M. and Zhang, L. and Zhong, N.S. and Zidarn, M., MACVIA-France, Fondation Partenariale FMC VIA-LR, CHU, Montpellier Cedex 5, 34295, France, INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny Le Bretonneux, France, European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Brussels, Belgium, Humboldt-Uniersität zu Berlin, Berlin, Germany, Department of Dermatology and Allergy, Comprehensive Allergy-Centre, Berlin Institute of Health, Berlin, Germany, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada, Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States, National Institute for Health and Welfare, Helsinki, Finland, Dept. of Otorhinolaryngology, Univ Hospitals Leuven, Louvain, Belgium, Academic Medical Center, Univ of Amsterdam, Amsterdam, Netherlands, Faculty of Medicine, Transylvania University, Brasov, Romania, Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, IMIM (Hospital del Mar Research Institute), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, Upper Airways Research Laboratory, ENT Dept., Ghent University Hospital, Ghent, Belgium, Dept. of Otolaryngology, Head and Neck Surgery, University of Mainz, Mainz, Germany, Hospital Civil de Guadalajara Dr Juan I Menchaca, Guadalarara, Mexico, iQ4U Consultants Ltd., London, United Kingdom, Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia, Woolcock Emphysema Centre, Sydney, Australia, Sydney Local Health District, Glebe, NSW, Australia, La Rochelle, France, Quebec Heart and Lung Institute, Laval University, Quebec City, QC, Canada, EIT Health France, Paris, France, Dept. of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, UCIBIO, REQUINTE, Faculty of Pharmacy, Competence Center on Active and Healthy Ageing, University of Porto (Porto4Ageing), Porto, Portugal, ProAR-Nucleo de Excelencia em Asma, Federal University of Bahia, Bahia, Brazil, WHO GARD Planning Group, Salvador, Brazil, Medical Consulting Czarlewski, Levallois, France, Department of Otorhino-Laryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, Medida, Lda Porto, Portugal, Athens Chest Hospital, 7th Resp. Med. Dept. and Asthma Center, Athens, Greece, Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R and D and DISMET), Naples, Italy, Center for Rhinology and Allergology, Wiesbaden, Germany, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Łódź, Poland, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, University of Medicine and Pharmacy, Hochiminh City, Viet Nam, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, KYomed INNOV, Montpellier, France, Faculty of Health Sciences and CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, CIRFF, Federico II University, Naples, Italy, Rhinology Unit and Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Dept. of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Division of Infection, Immunity and Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital P and A Kyriakou, University of Athens, Athens, Greece, Allergy Department, Pasteur Institute, Paris, France, Conseil General de l'Economie Ministere de l'Economie, de l'Industrie et du Numerique, Paris, France, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Pneumologie et Soins Intensifs Respiratoires, Hôpitaux Universitaires Paris, Centre Hôpital Cochin, Paris, France, Department of Internal Medicine, Medical University of Graz, Graz, Austria, Association Asthme et Allergie, Paris, France, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Crete, Greece, International Primary Care Respiratory Group IPCRG, Aberdeen, United Kingdom, Institute of Clinical Medicine, Institute of Health Sciences, Vilnius University, Faculty of Medicine, Vilnius, Lithuania, Department of Lung Diseases and Clinical Immunology, University of Turku and Terveystalo Allergy Clinic, Turku, Finland, FILHA, Finnish Lung Association, Helsinki, Finland, Unit of Geriatric Immunoallergol-ogy, University of Bari Medical School, Bari, Italy, Asthma UK, Mansell Street, London, United Kingdom, Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM and Sorbonne Université, Medical School Saint Antoine, Paris, France, Department of Medicine, University of Cape Town, Cape Town, South Africa, Dept. of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh, National Center of Expertise in Cognitive Stimulation (CEN STIMCO), Broca Hospital, Paris, France, Department of Biochemistry and Clinical Chemistry, Faculty of Pharmacy, Division of Laboratory Medicine, Warsaw Medical University, Warsaw, Poland, Global Alliance Against Chronic Respiratory Diseases (WHO GARD), Joensuu, Finland, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Termofscher Scientific, Uppsala, Sweden, Department of Respiratory Medicine and Allergology, University Hospital, Lund, Sweden, Department of Geriatrics, Montpellier University hospital, Montpellier, France, EA 2991 Euromov, University Montpellier, Montpellier, France, UOC Pneumologia, Istituto di Medicina Interna, F Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, National Heart and Lung Institute, Royal Brompton Hospital, Imperial College, London, United Kingdom, CHU, Dijon, France, Clinical Medicine, Laval's University, Quebec City, Canada, Medicine Department, Hôpital de la Malbaie, Quebec city, QC, Canada, Department of Clinical Pharmacy of Lithuanian, University of Health, Kaunas, Lithuania, Institute of Lung Health, Respiratory Biomedical Unit, University Hospitals of Leicester NHS Trust, Leicestershire, United Kingdom, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany, Municipality Pharmacy, Sarno, Italy, Personalized Medicine Clinic Asthma and Allergy, Humanitas University, Humanitas Research Hospital, Rozzano, Milan, Italy, Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron, ARADyAL Research Network, Barcelona, Spain, Regional Ministry of Health of Andalu-sia, Seville, Spain, Allergy and Asthma Associates of Southern California, Mission Viejo, CA, United States, ASA-Advanced Solutions Accelerator, Clapiers, France, Division of Allergy/Immunology, University of South Florida, Tampa, FL, United States, SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, Allergy and Immunology Laboratory, Metropolitan University, Simon Bolivar University, Barranquilla, Colombia, SLaai, Sociedad Lati-noamericana de Allergia, Asma e Immunologia, Barranquilla, Colombia, Chachava Clinic, David Tvildiani Medical University-AIETI Medical School, Grigol Robakidze University, Tbilisi, Georgia, Medical Faculty, ENT Department, Eskisehir Osmangazi University, Eskisehir, Turkey, Department of Health, Social Services and Public Safety, Belfast, Northern Ireland, United Kingdom, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal, PT Government Associate Laboratory, ICVS/3B's, Braga/Guimarães, Portugal, Ecole des Mines, Alès, France, Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester, University Hospital of South Manchester, Manchester, United Kingdom, Division of Respiratory and Allergic Diseases, Department of Respiratory Diseases, High Specialty Hospital A. Cardarelli, Naples, Italy, Allergy Service, University Hospital of Federal University of Santa Catarina (HU-UFSC), Florianópolis, Brazil, Cáritas Diocesana de Coimbra, Coimbra, Portugal, Ageing at Coimbra EIP-AHA Reference Site, Coimbra, Portugal, Medical Faculty Skopje, University Clinic of Pulmonology and Allergy, Skopje, North Macedonia, Sleep Unit, Department of Neurology, Hôpital Gui-de-Chauliac Montpellier, Inserm U1061, Montpellier, France, AQuAS, Barcelna, Spain, EUREGHA, European Regional and Local Health Association, Brussels, Belgium, Department of Medicine, Surgery and Dentistry Scuola Medica Salernitana, University of Salerno, Salerno, Italy, UPRES EA220, Pôle des Maladies des Voies Respiratoires, Hôpital Foch, Université Paris-Saclay, Suresnes, France, Farmacie Dei Golfi Group, Massa Lubrense, Italy, Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, United States, Clinic of Infectious, Chest Diseases, Dermatology and Allergology, Vilnius University, Vilnius, Lithuania, Clinical Reserch Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt, Clinic of Children's Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Global Allergy and Asthma Platform GAAPP, Vienna, Austria, Division of Allergy, Department of Pediatric Medicine, Bambino Gesù Children's Research Hospital Holy See, Rome, Italy, Reims, France, Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istambul, Turkey, Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland, National Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia, Allergy and Asthma Unit, Hospital San Bernardo Salta, Salta, Argentina, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico, Center of Allergy and Immunology, Georgian Association of Allergology and Clinical Immunology, Tbilisi, Georgia, Institute of Health Policy and Management iBMG, Erasmus University, Rotterdam, Netherlands, Immunology and Allergy Division, Clinical Hospital, University of Chile, Santiago, Chile, Centich: Centre d'Expertise National des Technologies de l'Information et de la Communication pour l'Autonomie, Gérontopôle Autonomie Longévité des Pays de la Loire, Conseil Régional des Pays de la Loire, Centre d'Expertise Partenariat Europeen d'Innovation pour un Vieillissement Actif et en Bonne Sante, Nantes, France, Department of Paediatrics and Child Health, University College Cork, Cork, Ireland, Université Paris-Sud, Service de Pneumologie, Hôpital Bicêtre, Inserm UMR-S999, Le Kremlin Bicêtre, France, Department of Medicine and Surgery, University of Salerno, Baronissi, Italy, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Hallym University College of Medicine, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, South Korea, Department of Clinical Immunology, Wrocław Medical University, Wrocław, Poland, Ukrainian Medical Stomatological Academy, Poltava, Ukraine, Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey, First Department of Family Medicine, Medical University of Lodz, Łódź, Poland, Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Berlin, Germany, Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Würzburg, Germany, National Research Center, Institute of Immunology, Federal Medicobiological Agency, Laboratory of Molecular Immunology, Moscow, Russian Federation, GARD, Geneva, Switzerland, Allergy and Asthma Center Westend, Berlin, Germany, Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Łódź, Poland, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden, Sach's Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Mattone Internazionale Program, Veneto Region, Italy, Departments of Internal Medicine and Pediatrics (Divisions of Allergy and Immunology), University of Tennessee College of Medicine, Germantown, TN, United States, Scottish Centre for Respiratory Research, Cardiovascular and Diabetes Medicine, Medical Research Institute, Ninewells Hospital, University of Dundee, Dundee, United Kingdom, Department of Paediatrics, Oslo University Hospital, Oslo, Norway, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, Imunoalergologia, Centro Hospitalar Universitário de Coimbra, Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Department of Pulmonary Medicine, CHU Sart-Tilman, GIGA I3 Research Group, Liege, Belgium, DG for Health and Social Care, Scottish Government, Edinburgh, United Kingdom, Department of Pulmonary Medicine, Rashid Hospital, Dubai, United Arab Emirates, Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Department of Medicine (RCSI), Bon Secours Hospital, Glasnevin, Dublin, Ireland, Kronikgune, International Centre of Excellence in Chronicity Research Barakaldo, Barakaldo, Bizkaia, Spain, Division of Clinical Immunology and Allergy, Laboratory of Behavioral Immunology Research, University of Mississippi Medical Center, Jackson, MS, United States, Tobacco Control Research Centre, Iranian Anti Tobacco Association, Tehran, Iran, Argentine Association of Allergy and Clinical Immunology, Buenos Aires, Argentina, Department of Pediatric Pneumology and Immunology, AG Molecular Allergology and Immunomodulation, Charité Medical University, Berlin, Germany, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, PNDR, Portuguese National Programme for Respiratory Diseases, Faculdade de Medicina de Lisboa, Lisbon, Portugal, Allergy and Asthma Medical Group and Research Center, San Diego, CA, United States, Department of Physiology, CHRU, University Montpellier, PhyMedExp, INSERM U1046, CNRS, UMR 9214, Montpellier, France, Croatian Pulmonary Society, Zagreb, Croatia, National Institute of Pneumology M Nasta, Bucharest, Romania, Clinic for Pulmonary Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbian Association for Asthma and COPD, Belgrade, Serbia, Regione Piemonte, Turin, Italy, Mexico City, Mexico, National Center for Research in Chronic Respiratory Diseases, Tishreen University School of Medicine, Latakia, Syrian Arab Republic, Syrian Private University, Damascus, Syrian Arab Republic, Faculty of Medicine and Surgery, University of Medicine, La Valette, Malta, Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino, Mauriziano Hospital, Turin, Italy, Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany, CRI-Clinical Research International-Ltd, Hamburg, Germany, Danish Commitee for Health Education, Copenhagen East, Denmark, Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy, MedScript Ltd., Paraparomu, New Zealand, OPC, Cambridge, United Kingdom, Johns Hopkins School of Medicine, Baltimore, MD, United States, Consortium of Pharmacies and Services COSAFER, Salerno, Italy, Scientific Centre of Children's Health under the Russian Academy of Medical Sciences, Moscow, Russian Federation, Center of Allergy, Immunology and Respiratory Diseases, Santa Fe, Argentina, Center for Allergy and Immunology, Santa Fe, Argentina, Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary, Die Hautambulanz and Rothhaar Study Center, Berlin, Germany, Department of Pharmacy, University of Naples Federico II, Naples, Italy, ENT Department, University Hospital of Kinshasa, Kinshasa, Democratic Republic Congo, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia, Dept. of Otolaryngology, Nippon Medical School, Tokyo, Japan, Centre Hospitalier Universitaire Pédiatrique Charles de Gaulle, Ouagadougou, Burkina Faso, Dept. of Comparative Medicine, Messerli Research Institute, University of Veterinary Medicine and Medical University, Vienna, Austria, EFA European Federation of Allergy and Airways Diseases Patients' Associations, Brussels, Belgium, Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic, Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea, Laboratoire HP2, Université Grenoble Alpes, Grenoble, France, INSERM, U1042, CHU de Grenoble, Grenoble, France, Allergy Unit, CUF-Porto Hospital and Institute, Porto, Portugal, Center for Research in Health Technologies and Information Systems, CINTESIS, Universidade do Porto, Porto, Portugal, Maladies Infectieuses et immunitaires, CHUL, Quebec City, QC, Canada, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany, Farmacias Holon, Lisbon, Portugal, Centre for Empowering Patients and Communities, Faulkland, Somerset, United Kingdom, Children's Hospital Srebrnjak, Zagreb, Croatia, School of Medicine, University J.J. Strossmayer, Osijek, Croatia, University Hospital 'Sv Ivan Rilski', Sofia, Bulgaria, Academic Centre of Primary Care, University of Aberdeen, Aberdeen, United Kingdom, Research in Real-Life, Cambridge, United Kingdom, Department of Otorhinolaryngology, University of Crete School of Medicine, Heraklion, Greece, Department of Nephrology and Endocrinology, Karolinska University Hospital, Stockholm, Sweden, Allergy Unit, Presidio Columbus, Catholic University of Sacred Heart, Rome, Italy, IRCCS Oasi Maria SS, Troina, Italy, Hospital de Clinicas, University of Parana, Paraná, Brazil, Division of Allergy Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel, Allergy and Respiratory Research Group, University of Edinburgh, Edinburgh, United Kingdom, Association of Finnish Pharmacists, Helsinki, Finland, Allergy and Clinical Immunology Department, Centro Médico-Docente la, Trinidad and Clínica El Avila, Caracas, Venezuela, Sociedad Paraguaya de Alergia Asma e Inmunologia, Asunción, Paraguay, Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil, European Health Futures Forum (EHFF), Dromahair, United Kingdom, Kyrgyzstan National Centre of Cardiology and Internal Medicine, Euro-Asian Respiratory Society, Bishkek, Kyrgyzstan, Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic, Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, Department of Respiratory Medicine, Hvidovre Hospital and University of Copenhagen, Copenhagen, Denmark, RNSA (Réseau National de Surveillance Aérobiologique), Brussieu, France, Sidkkids Hospitala and Institute of Health Policy, Management and Evaluation, Toronto, Canada, Department of ENT, Medical University of Graz, Graz, Austria, Pneumology and Allergy Department, CIBERES and Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Barcelona, Spain, Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria, NRC Institute of Immunology FMBA of Russia, Moscow, Russian Federation, Laboratory of Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russian Federation, Montevideo, Uruguay, Department of Public Health and Primary Care, Leiden University Medical Center (LUMC), Leiden, Netherlands, Department of Obstetrics and Gynaecology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium, Pulmonary Unit, Department of Medical Specialties, Arcispedale SMaria Nuova/IRCCS, AUSL di Reggio Emilia, Reggio Emilia, Italy, Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa, Italy, CNR Institute of Biomedicine and Molecular Immunology A Monroy, Palermo, Italy, Nova Southeastern University, Fort Lauderdale, FL, United States, Dept. of Otorhinolaryngology, HNO-Klinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany, Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada, Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States, Cyprus International Institute for Environmental, Public Health in Association with Harvard School of Public Health, Cyprus University of Technology, Limassol, Cyprus, Department of Pediatrics, Hospital Archbishop Makarios III, Nicosia, Cyprus, Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey, Allergy and Asthma Institute, Islamabad, Pakistan, Department of Paediatrics and Child Health, Red Cross Children's Hospital, Cape Town, South Africa, MRC Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa, Bull DSAS, Echirolles, France, Universidad Católica de Córdoba, Córdoba, Argentina, Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Beijing Institute of Otolaryngology, Beijing, China, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia, and National Hospital Organization, Tokyo National Hospital, Tokyo, Japan
- Abstract
Background: In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body: As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhi-nitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted "patient activation", (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Santé as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion: In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement. © The Author(s) 2019.
- Published
- 2019
11. 2019 ARIA Care pathways for allergen immunotherapy
- Author
-
Dana Wallace, Karin C. Lødrup Carlsen, M. T. Ventura, Igor Kaidashev, Stephen R. Durham, Motohiro Ebisawa, Oliver Pfaar, Hae-Sim Park, Daniel Laune, Wytske Fokkens, Antonella Muraro, Moises A. Calderon, Torsten Zuberbier, Mohamed H. Shamji, Mark S. Dykewicz, Roy Gerth van Wijk, Josep M. Antó, Samantha Walker, Petr Panzner, Giorgio Walter Canonica, Nelson Rosario, Juan Carlos Ivancevich, Holger J. Schünemann, Susanne Halken, Lorenzo Cecchi, Sinthia Bosnic-Anticevich, Violeta Kvedariene, Stefania La Grutta, João Fonseca, Marek L Kowalski, Tari Haahtela, Aziz Sheikh, Montserrat Fernandez-Rivas, Nhan Pham-Thi, Isabelle Bosse, Jean Bousquet, Lan Le, Despo Ierodiakonou, Tomohisa Iinuma, Lars Jacobsen, Christine Rolland, Gert Marien, Wienczyslawa Czarlewski, Glenis Scadding, Ioana Agache, Bolesław Samoliński, Olga Lourenço, Ludger Klimek, Yoshitaka Okamoto, Ulrich Wahn, Joaquim Mullol, Erkka Valovirta, Luigi Caraballo, Sanna Toppila-Salmi, Ioanna Tsiligianni, Derek K. Chu, Ruby Pawankar, Jean Luc Fauquert, Musa Khaitov, Jorg Kleine Tebbe, Jean-François Fontaine, Victoria Cardona, Désirée Larenas-Linemann, Thomas B. Casale, Omer Kalayci, Alvaro A. Cruz, Arunas Valiulis, Anna Bedbrook, Susanne Lau, Alkis Togias, H.-J. Malling, Claus Bachert, Dermot Ryan, Elísio Costa, Giovanni Passalacqua, Ignacio J. Ansotegui, Ana Todo Bom, Marek Jutel, Enrica Menditto, Piotr Kuna, Nikolaos G. Papadopoulos, Gregoire Mercier, Mario Sánchez-Borges, Karl-Christian Bergmann, Susan Waserman, Gunter J. Sturm, Maryline Valentin-Rostan, Arzu Yorgancioglu, Giovanni Battista Pajno, Jan Brozek, George Du Toit, Robyn E O'Hehir, Peter Hellings, Graham Roberts, uBibliorum, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Center for Rhinology and Allergology, National Institute of Allergy and Infectious Diseases [Bethesda] (NIAID-NIH), National Institutes of Health [Bethesda] (NIH), Department of Clinical Epidemiology and Biostatistics and Medicine, McMaster University [Hamilton, Ontario], Department of Allergy and Immunology, Hospital Quiròn Bizkaia Erandio, UPC Research Laboratories, Allergy Department, University of Crete [Heraklion] (UOC), Department of Allergy and Clinical Immunology, Transylvania University of Brasov, Universitat Pompeu Fabra [Barcelona] (UPF), Ghent University Hospital, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Department of Dermatology and Allergy [Berlin, Allemagne], Comprehensive Allergy Center [Berlin, Allemagne], Berlin Institute of Health (BIH)-Berlin Institute of Health (BIH), The University of Sydney, Woolcock Institute of Medical Research [Sydney], CHU Montpellier, Departments of Clinical Epidemiology and Biostatistics and Medicine [Ontario], Section of Allergy and Clinical Immunology [London, UK], Imperial College London-Royal Brompton Hospital-National Heart and Lung Institute, Humanitas Clinical and Research Center [Rozzano, Milan, Italy], Institute for Immunological Research (University of Cartagena), University of Cartagena, Allergy Section, Department of Internal Medicine, Vall d'Hebron University Hospital [Barcelona], Division of Allergy and Immunology, Department of Medicine, Creighton University, Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Universidade do Porto, Instituto de Biologia Molecular e Celular (IBMC), Universidade Federal da Bahia (UFBA), UCB Pharma, Colombes, Section of Allergy and Clinical Immunology, Imperial College London-Royal Brompton Hospital-National Heart and Lung Institute [UK], King‘s College London, Saint Louis University School of Medicine [St Louis], Sagamihara National Hospital, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Center of Research in Health Technologies and Information Systems (CINTESIS), Department of Allergology, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Helsinki University Hospital, Odense University Hospital, University Hospitals Leuven [Leuven], Chiba University Hospital, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Research Centre for Prevention and Health (RCPH), Department of Public Health [Copenhagen], Faculty of Health and Medical Sciences, University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU)-Faculty of Health and Medical Sciences, University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU)-Capital Region of Denmark, Department of Clinical Immunology, Wroclaw Medical University, Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Laboratory of Molecular Immunology [Moscow, Russian Federation] (National Research Center), Institute of Immunology [Moscow, Russian Federation]-Federal Medicobiological Agency [Moscow, Russian Federation], Hacettepe University = Hacettepe Üniversitesi, Allergy & Asthma Center Westend, Outpatient Clinic Hanf, Department of Immunology, Rheumatology and Allergy, Division of Internal Medicine, Asthma and Allergy, Medical University of Łódź (MUL)-Barlicki University Hospital, Vilnius University [Vilnius], CNR-IBIM : National Research Council-Institute of Biomedicine and Molecular Immunology, Department of Pediatric Pneumology and Immunology, Ho Chi Minh City University of Technology (HCMUT), University of Oslo (UiO), Faculty of Health Sciences and CICS-UB (Health Sciences Research Centre), 'Federico II' University of Naples Medical School, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Food Allergy Referral Centre Veneto Region [Padua, Italy], Universita degli Studi di Padova, Monash University [Melbourne], Department of Otorhinolaryngology, Department of Pediatrics, Allergy Unit, University of Messina, Ajou University School of Medicine, Department of Allergology and Clinical Immunology, Medical Faculty in Pilsen-Charles University in Prague - the First Faculty of Medicine, Allergy and Respiratory Diseases, University of Genoa (UNIGE), Saint Mary's Hospital [London], St Mary's Hospital [London], Department of Pediatrics, Nippon Medical School, Pediatrics, Universidade Federal do Paraná (UFPR), Medical Centre, Woodbrook Medical Centre, Medical University of Warsaw - Poland, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw - Poland-Faculté de Pharmacie de Paris, Department of Allergy and Clinical Immunology [Caracas, Venezuela], Centro Medico-Docente La Trinidad, The Royal National Throat, Nose and Ear Hospital, Imperial College London, Centre for Population Health Sciences, University of Edinburgh, Medical University Graz, University of Coimbra [Portugal] (UC), Vilnius University Clinic of Children's Diseases, Suomen Terveystalo Allergy Clinic, Università degli studi di Bari Aldo Moro (UNIBA), Department for Pediatric Pneumology and Immunology, Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, (MRC), Guy's Hospital [London], Nova Southeastern University (NSU), Department of Pulmonology, Manisa Celal Bayar University, Department of Dermatology, Medical School-Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Association Asthme et Allergie, Internal Medicine, Bousquet, J., Pfaar, O., Togias, A., Schunemann, H. J., Ansotegui, I., Papadopoulos, N. G., Tsiligianni, I., Agache, I., Anto, J. M., Bachert, C., Bedbrook, A., Bergmann, K. -C., Bosnic-Anticevich, S., Bosse, I., Brozek, J., Calderon, M. A., Canonica, G. W., Caraballo, L., Cardona, V., Casale, T., Cecchi, L., Chu, D., Costa, E., Cruz, A. A., Czarlewski, W., Durham, S. R., Du Toit, G., Dykewicz, M., Ebisawa, M., Fauquert, J. L., Fernandez-Rivas, M., Fokkens, W. J., Fonseca, J., Fontaine, J. -F., Gerth van Wijk, R., Haahtela, T., Halken, S., Hellings, P. W., Ierodiakonou, D., Iinuma, T., Ivancevich, J. C., Jacobsen, L., Jutel, M., Kaidashev, I., Khaitov, M., Kalayci, O., Kleine Tebbe, J., Klimek, L., Kowalski, M. L., Kuna, P., Kvedariene, V., La Grutta, S., Larenas-Linemann, D., Lau, S., Laune, D., Le, L., Lodrup Carlsen, K., Lourenco, O., Malling, H. -J., Marien, G., Menditto, E., Mercier, G., Mullol, J., Muraro, A., O'Hehir, R., Okamoto, Y., Pajno, G. B., Park, H. -S., Panzner, P., Passalacqua, G., Pham-Thi, N., Roberts, G., Pawankar, R., Rolland, C., Rosario, N., Ryan, D., Samolinski, B., Sanchez-Borges, M., Scadding, G., Shamji, M. H., Sheikh, A., Sturm, G. J., Todo Bom, A., Toppila-Salmi, S., Valentin-Rostan, M., Valiulis, A., Valovirta, E., Ventura, M. -T., Wahn, U., Walker, S., CORBO UGULINO, Wallace, Waserman, S., Yorgancioglu, A., Zuberbier, T., Hospital Quirónsalud Bizkaia [Bilbao], Sagamihara National Hospital [Kanagawa, Japan], Universidade do Porto = University of Porto, University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH)-Faculty of Health and Medical Sciences, University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH)-Capital Region of Denmark, Wrocław Medical University, Università degli Studi di Padova = University of Padua (Unipd), Charles University [Prague] (CU)-Medical Faculty in Pilsen, Università degli studi di Genova = University of Genoa (UniGe), Centro Médico Docente La Trinidad, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), and Hibade, Monique
- Subjects
Cost effectiveness ,[SDV]Life Sciences [q-bio] ,Cost-Benefit Analysis ,Comorbidity ,medicine.disease_cause ,0302 clinical medicine ,Allergen ,Cost of Illness ,Immunology and Allergy ,Medicine ,030212 general & internal medicine ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,Precision Medicine ,mHealth ,Children ,media_common ,Allergen immunotherapy ,Rhinitis ,Disease Management ,3. Good health ,[SDV] Life Sciences [q-bio] ,rhiniti ,Treatment Outcome ,Practice Guidelines as Topic ,Critical Pathways ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Disease Susceptibility ,[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology ,medicine.medical_specialty ,[SDV.IMM] Life Sciences [q-bio]/Immunology ,Attitude of Health Personnel ,Immunology ,Clinical Decision-Making ,03 medical and health sciences ,Pharmacotherapy ,rhinitis ,stratification ,children ,media_common.cataloged_instance ,Animals ,Humans ,European union ,Intensive care medicine ,allergen immunotherapy, asthma, children, mHealth, rhinitis, stratification ,Asthma ,business.industry ,Allergens ,asthma ,medicine.disease ,Rhinitis, Allergic ,Review article ,030228 respiratory system ,Desensitization, Immunologic ,allergen immunotherapy ,Stratification ,business ,Biomarkers - Abstract
Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including health professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as on the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow up of patients. This article is protected by copyright. All rights reserved.
- Published
- 2019
12. Electronic Clinical Decision Support System for allergic rhinitis management: MASK e-CDSS
- Author
-
Paulo Augusto Moreira Camargos, Sinthia Bosnic-Anticevich, Thomas B. Casale, Omer Kalayci, Ioana Agache, Massimo Triggiani, Giorgio Walter Canonica, David Price, Caterina Bucca, Tari Haahtela, Dermot Ryan, Joaquim Mullol, Martin Wagenmann, Erkka Valovirta, Magnus Wickman, Ludger Klimek, F. Estelle R. Simons, Davide Caimmi, Piotr Kuna, Jean Bousquet, Govert De Vries, Arunas Valiulis, Arzu Yorgancioglu, Jan Brozek, Bolesław Samoliński, Ruth Murray, Sylvie Arnavielhe, Peter Valentin Tomazic, Claus Bachert, Désirée Larenas Linnemann, Nikolaos G. Papadopoulos, Phil Lieberman, Mário Morais-Almeida, W. Carr, Anna Bedbrook, João Fonseca, Anne Lise Courbis, Violeta Kvedariene, Karl Christian Bergmann, Gérard Dray, Robyn E O'Hehir, Michiel van Eerd, LGI2P, IMT Mines Ales, University of Montpellier, Ales, France, Department of Allergic Diseases, Medscript NZ Ltd, Kapiti Coast, Paraparaumu Beach, New Zealand, Kyomed, Montpellier, France, Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France, Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France, Peercode B.V., Geldermalsen, Netherlands, Transylvania University Brasov, Brasov, Romania, Immunoallergy Department, CUF Descobertas Hospital, Lisbon, Portugal, ENT Department, Upper Airways Research Laboratory, Ghent University Hospital, Ghent, Belgium, Allergy-Centre-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany, Woolcock Institute of Medical Research, University of Sydney and Sydney Local Health District, Glebe, NSW, Australia, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada, Hospital City of Health and Science of Torino, University Pneumology Unit-AOU Molinette, Turin, Italy, Department of Pediatrics, Medical School, Federal University of Minas Gerais, Belo Horizonte, Brazil, Personalized Medicine Asthma & Allergy Clinic, Humanitas University & Research Hospital, Milan, Italy, Allergy and Asthma Associates of Southern California, Mission Viejo, CA, United States, Division of Allergy and Immunology, University of South Florida Morsani College of Medicine, Tampa, FL, United States, CINTESIS, Faculdade de Medicina da Universidade do Porto & MEDIDA, LDA, Porto, Portugal, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Department of Pediatric Allergy, Hacettepe University School of Medicine, Ankara, Turkey, Center for Rhinology and Allergology, Wiesbaden, Germany, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Department of Pathology, Faculty of Medicine, Clinic of Infectious, Chest Diseases, Dermatology and Allergology, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania, Clínica de Alergia, Asma y Pediatría, Hospital Médica Sur, Mexico City, Mexico, Divisions of Allergy and Immunology, Department of Internal Medicine and Pediatrics, University of Tennessee College of Medicine, Germantown, TN, United States, ENT Department, Hospital Clinic, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, Universitat de Barcelona, Barcelona, Spain, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia, Division of Infection, Immunity & Respiratory Medicine, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece, Observational and Pragmatic Research Institute, Singapore, Singapore, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh Medical School, Edinburgh, United Kingdom, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Department of Pediatrics and Child Health, Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Winnipeg, Canada, Department of ENT, Medical University of Graz, Graz, Austria, Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy, Department of Public Health, Institute of Clinical Medicine, Clinic of Children's Diseases, Institute of Health Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Department of Lung Diseases and Clinical Allergology, University of Turku, Turku, Finland, Allergy Clinic, Terveystalo, Turku, Finland, Department of Otorhinolaryngology, HNO-Klinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany, Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden, Department of Pulmonology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey, INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Montigny le Bretonneux, France, CHU Montpellier, Montpellier, France, Department of Dermatology, Allergology and Venereology, Clinicum, HUS Inflammation Center, IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT), Laboratoire de Génie Informatique et Ingénierie de Production (LGI2P), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Kyomed, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Department of Allergy and Clinical Immunology, Transylvania University of Brasov, Immunoallergy Department, CUF-Descobertas Hospital, Ghent University Hospital, Woolcock Institute of Medical Research [Sydney], The University of Sydney, McMaster University [Hamilton, Ontario], Allergy & Respiratory Diseases, University of Genoa (UNIGE)-Department of Internal Medicine (DIMI), Allergy & Asthma Associates, University of California [Irvine] (UCI), University of California-University of California, University of South Florida [Tampa] (USF), Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto, Department of Dermatology, Helsinki University Hospital-Skin and Allergy Hospital, Hacettepe University = Hacettepe Üniversitesi, German Society for Otorhinolaryngology HNS, Medical University of Łódź (MUL), Hospital Medica Sur [Mexico City, Mexico], Division of Allergy Immunology, Department of Medicine-The University of Tennessee Health Science Center [Memphis] (UTHSC), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Centre for integrative Physiology, University of Edinburgh, Allergy and Respiratory Research Group, Medical University of Warsaw - Poland, Division of Clinical Immunology and Allergy, Università degli studi di Napoli Federico II, Vilnius University Clinic of Children's Diseases, Department of Lung Diseases & Clinical Allergology, University of Turku, Sachs' Children's Hospital, Department of Pulmonology, Manisa Celal Bayar University, and Çocuk Sağlığı ve Hastalıkları
- Subjects
Telemedicine ,Decision support system ,Evidence-based practice ,Allergy ,Computer science ,IMPACT ,Immunology ,Clinical decision support system ,VALIDATION ,03 medical and health sciences ,User-Computer Interface ,0302 clinical medicine ,Quality of life (healthcare) ,QUALITY-OF-LIFE ,Information system ,medicine ,Immunology and Allergy ,Humans ,ta318 ,030212 general & internal medicine ,Disease management (health) ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,ComputingMilieux_MISCELLANEOUS ,Disease Management ,Guideline ,medicine.disease ,Decision Support Systems, Clinical ,Mobile Applications ,Rhinitis, Allergic ,3. Good health ,030228 respiratory system ,3121 General medicine, internal medicine and other clinical medicine ,Evidence-Based Practice ,ASTHMA ,[INFO.INFO-ES]Computer Science [cs]/Embedded Systems ,Medical emergency ,Smartphone ,VISUAL ANALOG SCALE ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Background: Allergic rhinitis (AR) management has changed in recent years following the switch from the concept of disease severity to the concept of disease control, publication of the AR clinical decision support system (CDSS) and development of mobile health (m-health) tools for patients (eg Allergy Diary). The Allergy Diary Companion app for healthcare providers is currently being developed and will be launched in 2018. It incorporates the AR CDSS to provide evidence-based treatment recommendations, linking all key stakeholders in AR management. Objective: To produce an electronic version of the AR CDSS (e-CDSS) for incorporation into the Allergy Diary Companion, to describe the app interfaces used to collect information necessary to inform the e-CDSS and to summarize some key features of the Allergy Diary Companion. Methods: The steps involved in producing the e-CDSS and incorporating it into the Allergy Diary Companion were (a) generation of treatment management scenarios; (b) expert consensus on treatment recommendations; (c) generation of electronic decisional algorithms to describe all AR CDSS scenarios; (d) digitization of these algorithms to form the e-CDSS; and (e) embedding the e-CDSS into the app to permit easy user e-CDSS interfacing. Results: Key experts in the AR field agreed on the AR CDSS approach to AR management and on specific treatment recommendations provided by Allergy Diary Companion. Based on this consensus, decision processes were developed and programmed into the Allergy Diary Companion using Titanium Appcelerator (JavaScript) for IOS tablets. To our knowledge, this is the first time the development of any m-health tool has been described in this transparent and detailed way, providing confidence, not only in the app, but also in the provided management recommendations. Conclusion: The Allergy Diary Companion for providers provides guideline and expert-endorsed AR management recommendations. [MASK paper No 32]. © 2018 John Wiley & Sons Ltd
- Published
- 2018
13. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence
- Author
-
Bousquet, J. and Arnavielhe, S. and Bedbrook, A. and Bewick, M. and Laune, D. and Mathieu-dupas, E. and Murray, R. and Onorato, G.L. and Pépin, J.L. and Picard, R. and Portejoie, F. and Costa, E. and Fonseca, J. and Lourenço, O. and Morais-Almeida, M. and Todo-bom, A. and Cruz, A.A. and Silva, J.D. and Serpa, F.S. and Illario, M. and Menditto, E. and Cecchi, L. and Monti, R. and Napoli, L. and Ventura, M.T. and De Feo, G. and Larenas-linnemann, D. and Fuentes Perez, M. and Huerta Villabolos, Y.R. and Rivero-yeverino, D. and Rodriguez-zagal, E. and Amat, F. and Annesi-maesano, I. and Bosse, I. and Demoly, P. and Devillier, P. and Fontaine, J.F. and Just, J. and Kuna, T.P. and Samolinski, B. and Valiulis, A. and Emuzyte, R. and Kvedariene, V. and Ryan, D. and Sheikh, A. and Schmidt-grendelmeier, P. and Klimek, L. and Pfaar, O. and Bergmann, K.C. and Mösges, R. and Zuberbier, T. and Roller-wirnsberger, R.E. and Tomazic, P. and Fokkens, W.J. and Chavannes, N.H. and Reitsma, S. and Anto, J.M. and Cardona, V. and Dedeu, T. and Mullol, J. and Haahtela, T. and Salimäki, J. and Toppila-Salmi, S. and Valovirta, E. and Gemicioğlu, B. and Yorgancioglu, A. and Papadopoulos, N. and Prokopakis, E.P. and Bosnic-anticevich, S. and O’hehir, R. and Ivancevich, J.C. and Neffen, H. and Zernotti, E. and Kull, I. and Melen, E. and Wickman, M. and Bachert, C. and Hellings, P. and Palkonen, S. and Bindslev-jensen, C. and Eller, E. and Waserman, S. and Sova, M. and De Vries, G. and van Eerd, M. and Agache, I. and Casale, T. and Dykewickz, M. and Naclerio, R.N. and Okamoto, Y. and Wallace, D.V. and Hellings, P.W. and Aberer, W. and Akdis, C.A. and Akdis, M. and Alberti, M.R. and Almeida, R. and Angles, R. and Ansotegui, I.J. and Arnavielle, S. and Asayag, E. and Asarnoj, A. and Arshad, H. and Avolio, F. and Bacci, E. and Baiardini, I. and Barbara, C. and Barbagallo, M. and Baroni, I. and Barreto, B.A. and Basagana, X. and Bateman, E.D. and Bedolla-Barajas, M. and Beghé, B. and Bel, E.H. and Bennoor, K.S. and Benson, M. and Bertorello, L. and Białoszewski, A.Z. and Bieber, T. and Bialek, S. and Bjermer, L. and Blain, H. and Blasi, F. and Blua, A. and Bochenska Marciniak, M. and Bogus-Buczynska, I. and Boner, A.L. and Bonini, M. and Bonini, S. and Bosnic-Anticevich, C.S. and Bouchard, J. and Boulet, L.P. and Bourret, R. and Bousquet, P.J. and Braido, F. and Briedis, V. and Brightling, C.E. and Brozek, J. and Bucca, C. and Buhl, R. and Buonaiuto, R. and Panaitescu, C. and Burguete Cabañas, M.T. and Burte, E. and Bush, A. and Caballero-Fonseca, F. and Caillot, D. and Caimmi, D. and Calderon, M.A. and Camargos, P.A.M. and Camuzat, T. and Canfora, G. and Canonica, G.W. and Carlsen, K.H. and Carreiro-Martins, P. and Carriazo, A.M. and Carr, W. and Cartier, C. and Castellano, G. and Cepeda, A.M. and Chen, Y. and Chiron, R. and Chivato, T. and Chkhartishvili, E. and Chuchalin, A.G. and Chung, K.F. and Ciaravolo, M.M. and Ciceran, A. and Cingi, C. and Ciprandi, G. and Carvalho Coehlo, A.C. and Colas, L. and Colgan, E. and Coll, J. and Conforti, D. and Correia de Sousa, J. and Cortés-Grimaldo, R.M. and Corti, F. and Costa-Dominguez, M.C. and Courbis, A.L. and Cox, L. and Crescenzo, M. and Custovic, A. and Czarlewski, W. and Dahlen, S.E. and Dario, C. and da Silva, J. and Dauvilliers, Y. and Darsow, U. and De Blay, F. and De Carlo, G. and de Fátima Emerson, M. and De Martino, B. and de Paula Motta Rubini, N. and Deleanu, D. and Denburg, J.A. and Di Capua Ercolano, S. and Di Carluccio, N. and Didier, A. and Dokic, D. and Dominguez-Silva, M.G. and Douagui, H. and Dray, G. and Dubakiene, R. and Durham, S.R. and Du Toit, G. and Dykewicz, M.S. and El-Gamal, Y. and Eklund, P. and Farrell, J. and Farsi, A. and Ferreira de Mello, J., Jr. and Ferrero, J. and Fink-Wagner, A. and Fiocchi, A. and Fonseca, J.A. and Forti, S. and Fuentes-Perez, J.M. and Gálvez-Romero, J.L. and Gamkrelidze, A. and Garcia-Aymerich, J. and García-Cobas, C.Y. and Garcia-Cruz, M.H. and Genova, S. and George, C. and Gereda, J.E. and Gerth van Wijk, R. and Gomez, R.M. and Gómez-Vera, J. and González Diaz, S. and Gotua, M. and Grisle, I. and Guidacci, M. and Guldemond, N.A. and Gutter, Z. and Guzmán, M.A. and Hajjam, J. and Hernández, L. and Hourihane, J.O.’.B. and Huerta-Villalobos, Y.R. and Humbert, M. and Iaccarino, G. and Jares, E.J. and Jassem, E. and Johnston, S.L. and Joos, G. and Jung, K.S. and Jutel, M. and Kaidashev, I. and Kalayci, O. and Kalyoncu, A.F. and Karjalainen, J. and Kardas, P. and Keil, T. and Keith, P.K. and Khaitov, M. and Khaltaev, N. and Kleine-Tebbe, J. and Kowalski, M.L. and Kuitunen, M. and Kuna, P. and Kupczyk, M. and Krzych-Fałta, E. and Lacwik, P. and Lauri, D. and Lavrut, J. and Le, L.T.T. and Lessa, M. and Levato, G. and Li, J. and Lieberman, P. and Lipiec, A. and Lipworth, B. and Lodrup Carlsen, K.C. and Louis, R. and Luna-Pech, J.A. and Maciej, K. and Magnan, A. and Mahboub, B. and Maier, D. and Mair, A. and Majer, I. and Malva, J. and Mandajieva, E. and Manning, P. and De Manuel Keenoy, E. and Marshall, G.D. and Masjedi, M.R. and Maspero, J.F. and Matta Campos, J.J. and Matos, A.L. and Maurer, M. and Mavale-Manuel, S. and Mayora, O. and Medina-Avalos, M.A. and Melén, E. and Melo-Gomes, E. and Meltzer, E.O. and Mercier, J. and Miculinic, N. and Mihaltan, F. and Milenkovic, B. and Moda, G. and Mogica-Martinez, M.D. and Mohammad, Y. and Momas, I. and Montefort, S. and Mora Bogado, D. and Morato-Castro, F.F. and Mota-Pinto, A. and Moura Santo, P. and Münter, L. and Muraro, A. and Naclerio, R. and Nadif, R. and Nalin, M. and Namazova-Baranova, L. and Niedeberger, V. and Nekam, K. and Neou, A. and Nieto, A. and Nogueira-Silva, L. and Nogues, M. and Novellino, E. and Nyembue, T.D. and O’hehir, R.E. and Odzhakova, C. and Ohta, K. and Okubo, K. and Ortega Cisneros, M. and Ouedraogo, S. and Pali-Schöll, I. and Panzner, P. and Papadopoulos, N.G. and Park, H.S. and Papi, A. and Passalacqua, G. and Paulino, E. and Pawankar, R. and Pedersen, S. and Pereira, A.M. and Persico, M. and Phillips, J. and Pigearias, B. and Pin, I. and Pitsios, C. and Plavec, D. and Pohl, W. and Popov, T.A. and Potter, P. and Pozzi, A.C. and Price, D. and Puy, R. and Pugin, B. and Pulido Ross, R.E. and Przemecka, M. and Rabe, K.F. and Raciborski, F. and Rajabian-Soderlund, R. and Ribeirinho, I. and Rimmer, J. and Rizzo, J.A. and Rizzo, M.C. and Robalo-Cordeiro, C. and Rodenas, F. and Rodo, X. and Rodriguez Gonzalez, M. and Rodriguez-Mañas, L. and Rolland, C. and Rodrigues Valle, S. and Roman Rodriguez, M. and Romano, A. and Rolla, G. and Romano, M. and Rosado-Pinto, J. and Rosario, N. and Rottem, M. and Sagara, H. and Sanchez-Borges, M. and Sastre-Dominguez, J. and Scadding, G.K. and Schunemann, H.J. and Scichilone, N. and Schmid-Grendelmeier, P. and Shamai, S. and Sierra, M. and Simons, F.E.R. and Siroux, V. and Sisul, J.C. and Skrindo, I. and Solé, D. and Somekh, D. and Sondermann, M. and Sooronbaev, T. and Sorensen, M. and Sorlini, M. and Spranger, O. and Stellato, C. and Stelmach, R. and Stukas, R. and Sunyer, J. and Strozek, J. and Szylling, A. and Tebyriçá, J.N. and Thibaudon, M. and To, T. and Tomazic, P.V. and Trama, U. and Triggiani, M. and Suppli Ulrik, C. and Urrutia-Pereira, M. and Valenta, R. and Valero, A. and van Ganse, E. and van Hague, M. and Vandenplas, O. and Vezzani, G. and Vasankari, T. and Vatrella, A. and Verissimo, M.T. and Viart, F. and Viegi, G. and Vicheva, D. and Vontetsianos, T. and Wagenmann, M. and Walker, S. and Wallace, D. and Wang, D.Y. and Werfel, T. and Westman, M. and Williams, D.M. and Williams, S. and Wilson, N. and Wright, J. and Wroczynski, P. and Yakovliev, P. and Yawn, B.P. and Yiallouros, P.K. and Yusuf, O.M. and Zar, H.J. and Zhang, L. and Zhong, N. and Zernotti, M.E. and Zidarn, M. and Zubrinich, C. and Zurkuhlen, A., MACVIA-France, Fondation Partenariale FMC VIA-LR, CHRU Arnaud de Villeneuve, 371 Avenue du Doyen Gaston Giraud, Montpellier, France, INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France, Euforea, Brussels, Belgium, KYomed-INNOV, Montpellier, France, iQ4U Consultants Ltd, London, United Kingdom, MedScript Ltd, Dundalk, Co Louth, Ireland, Laboratoire HP2, Grenoble, INSERM, U1042, Université Grenoble Alpes, Grenoble, France, CHU de Grenoble, Grenoble, France, Conseil Général de l’Economie Ministère de l’Economie, de l’Industrie et du Numérique, Paris, France, UCIBIO, REQUINTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing, University of Porto (Porto4Ageing), Porto, Portugal, Center for Health Technology and Services Research, - CINTESIS, Faculdade de Medicina, Universidade do Porto, Porto, Portugal, Medida, Lda, Porto, Portugal, Faculty of Health Sciences and CICS – UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal, Imunoalergologia, Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of Coimbra, Coimbra, Portugal, ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Vitória da Conquista, Brazil, WHO GARD Planning Group, Salvador, Brazil, Allergy Service, University Hospital of Federal University of Santa Catarina (HU-UFSC), Florianópolis, Brazil, Asthma Reference Center, Escola Superior de Ciencias da Santa Casa de Misericordia de Vitoria, Vitória, Esperito Santo, Brazil, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&D and DISMET), Naples, Italy, CIRFF, Federico II University, Naples, Italy, SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino & Mauriziano Hospital, Torino, Italy, Consortium of Pharmacies and Services COSAFER, Salerno, Italy, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Salerno, Italy, Center of Excellence in Asthma and Allergy, Hospital Médica Sur, México City, Mexico, Mexico City, Mexico, Puebla, Puebla, Mexico, Ciutad Mexico, Mexico, Allergology Department, Centre de l’Asthme et des Allergies Hôpital d’Enfants Armand-Trousseau (APHP), Paris, France, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Sorbonne Universités, Equipe EPAR, Paris, 75013, France, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM, UPMC Sorbonne Université, Medical School Saint Antoine, Paris, France, La Rochelle, France, Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France, UPRES EA220, Pôle des Maladies des Voies Respiratoires, Hôpital Foch, Université Paris-Saclay, Suresnes, France, Reims, France, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Clinic of Children’s Diseases, and Institute of Health Sciences Department of Public Health, Vilnius University Institute of Clinical Medicine, Vilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium, Clinic of Children’s Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Woodbrook Medical Centre, Loughborough, United Kingdom, Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Medical School, Edinburgh, United Kingdom, Centre of Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom, Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zürich, Switzerland, Center for Rhinology and Allergology, Wiesbaden, Germany, Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, Comprehensive Allergy, -Centre, -Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany, Global Allergy and Asthma European Network (GA2LEN), Berlin, Germany, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany, CRI-Clinical Research International-Ltd, Hamburg, Germany, Department of Internal Medicine, Medical University of Graz, Graz, Austria, Department of ENT, Medical University of Graz, Graz, Austria, Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, Netherlands, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, IMIM (Hospital del Mar Research Institute), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, Allergy Section, Department of Internal Medicine, Hospital Vall ‘dHebron & ARADyAL Research Network, Barcelona, Spain, AQuAS, Barcelona, Spain, EUREGHA, European Regional and Local Health Association, Brussels, Belgium, Rhinology Unit and Smell Clinic, ENT Department, Hospital Clínic, University of Barcelona, Barcelona, Spain, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Association of Finnish Pharmacists, Helsinki, Finland, Department of Lung Diseases and Clinical Immunology, University of Turku, Turku, Finland, Terveystalo Allergy Clinic, Turku, Finland, Department of Pulmonary Diseases, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey, Department of Pulmonary Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey, GARD Executive Committee, Manisa, Turkey, Center for Pediatrics and Child Health, Institute of Human Development, Royal Manchester Children’s Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children’s Hospital 'P&A Kyriakou', University of Athens, Athens, 11527, Greece, Department of Otorhinolaryngology, University of Crete School of Medicine, Heraklion, Greece, Woolcock Institute of Medical Research, University of Sydney and Sydney Local Health District, Glebe, NSW, Australia, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia, Department of Immunology, Monash University, Melbourne, VIC, Australia, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Director of Center of Allergy, Immunology and Respiratory Diseases, Santa Fe, Argentina Center for Allergy and Immunology, Santa Fe, Argentina, Universidad Católica de Córdoba, Córdoba, Argentina, Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden, Sachs’ Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden, Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium, Department of Otorhinolaryngology, Univ Hospitals Leuven, Louvain, Belgium, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, EFA European Federation of Allergy and Airways Diseases Patients’ Associations, Brussels, Belgium, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada, University Hospital Olomouc, Olomouc, Czech Republic, Peercode BV, Geldermalsen, Netherlands, Faculty of Medicine, Transylvania University, Brasov, Romania, Division of Allergy/Immunology, University of South Florida, Tampa, United States, Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, United States, Johns Hopkins School of Medicine, Baltimore, MD, United States, Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Nova Southeastern University, Fort Lauderdale, FL, United States, University Hospital, Montpellier, France, MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France, VIMA. INSERM U 1168, VIMA: Ageing and chronic diseases Epidemiological and public health approaches, Villejuif, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France, Laboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium, Department of Dermatology, Medical University of Graz, Graz, Austria, Transylvania University Brasov, Brasov, Romania, Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland, Chairman of the Council of Municipality of Salerno, Italy, Center for Health Technology and Services Research-CINTESIS, Faculdade de Medicina, Universidade do Porto, and Medida, Lda Porto, Portugal, Allergology department, Centre de l’Asthme et des Allergies Hôpital d’Enfants Armand-Trousseau (APHP), Sorbonne Université, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Equipe EPAR, Paris, France, Innovación y nuevas tecnologías, Salud Sector sanitario de Barbastro, Barbastro, Spain, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM and Sorbonne Université, Medical School Saint Antoine, Paris, France, Department of Allergy and Immunology, Hospital Quirón Bizkaia, Erandio, Spain, KYomed INNOV, Montpellier, France, Argentine Society of Allergy and Immunopathology, Buenos Aires, Argentina, Clinical Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, and Astrid Lindgren Children’s Hospital, Department of Pediatric Pulmonology and Allergy, Karolinska University Hospital, Stockholm, Sweden, David Hide Asthma and Allergy Research Centre, Isle of Wight, United Kingdom, Regionie Puglia, Bari, Italy, Regione Liguria, Genoa, Italy, Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium, Allergy and Respiratory Diseases, Ospedale Policlinico San Martino, University of Genoa, Italy, PNDR, Portuguese National Programme for Respiratory Diseases, Faculdade de Medicina de Lisboa, Lisbon, Portugal, Director of the Geriatric Unit, Department of Internal Medicine (DIBIMIS), University of Palermo, Italy, Telbios SRL, Milan, Italy, Universidade do Estado do Pará, Belem, Brazil, Department of Medicine, University of Cape Town, Cape Town, South Africa, Hospital Civil de Guadalajara Dr Juan I Menchaca, Guadalarara, Mexico, Section of Respiratory Disease, Department of Oncology, Haematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy, Depart-ment of Respiratory Medicine, Academic Medical Center (AMC), University of Amsterdam, Netherlands, Comprehensive Allergy Center Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Deptt of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh, Centre for Individualized Medicine, Department of Pediatrics, Faculty of Medicine, Linköping, Sweden, Depart-ment of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Poland, BIEBER. Department of Dermatology and Allergy, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany, Dept of Biochemistry and Clinical Chemistry, Faculty of Pharmacy with the Division of Laboratory Medicine, Warsaw Medical University, Warsaw, Poland, Department of Respiratory Medicine and Allergology, University Hospital, Lund, Sweden, Department of Geriatrics, Montpellier University Hospital, Montpellier, France, EA 2991, Euromov, University Montpellier, France, Department of Pathophysiology and Transplantation, University of Milan, IRCCS Fondazione Ca’Granda Ospedale Maggiore Policlinico, Milan, Italy, Argentine Association of Respiratory Medicine, Buenos Aires, Argentina, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Poland, Pediatric Department, University of Verona Hospital, Verona, Italy, Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, Second University of Naples and Institute of Translational Medicine, Italian National Research Council, Italy, Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and and Sydney Local Health District, Glebe, NSW, Australia, Allergist, La Rochelle, France, Associate professor of clinical medecine, Laval’s University, Quebec city, Head of medecine department, Hôpital de la MalbaieQC, Canada, Quebec Heart and Lung Institute, Laval University, Québec City, QC, Canada, Centre Hospitalier Valenciennes, France, Head of Department of Clinical Pharmacy of Lithuanian University of Health Sciences, Kaunas, Lithuania, Institute of Lung Health, Respiratory Biomedical Unit, University Hospitals of Leicester NHS Trust, Leicestershire, United Kingdom, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom, Department of Health Research Methods, Evidence and Impact, Division of Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada, Chief of the University Pneumology Unit-AOU Molinette, Hospital City of Health and Science of Torino, Italy, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany, Pharmacist, Municipality Pharmacy, Sarno, Italy, University of Medicine and Pharmacy Victor Babes, Timisoara, Romania, Instituto de Pediatria, Hospital Zambrano Hellion Tec de Monterrey, Monterrey, Mexico, Imperial College and Royal Brompton Hospital, London, United Kingdom, Centro Medico Docente La Trinidad, CaRacas, Venezuela, Regional Director Assofarm Campania and Vice President of the Board of Directors of Cofaser, Salerno, Italy, Service de pneumologie, CHU et université d’Auvergne, Clermont-Ferrand, France, Department of Respiratory Diseases, Montpellier University Hospital, France, Imperial College London-National Heart and Lung Institute, Royal Brompton Hospital NHS, London, United Kingdom, Federal University of Minas Gerais, Medical School, Department of Pediatrics, Belo Horizonte, Brazil, Assitant Director General, Montpellier, Région Occitanie, France, Mayor of Sarno and President of Salerno Province, Director, Anesthesiology Service, Sarno 'Martiri del Villa Malta' Hospital, Italy, Allergy Section, Department of Internal Medicine, Hospital Vall d’Hebron & ARADyAL Spanish Research Network, Barcelona, Spain, Department of Paediatrics, Oslo University Hospital and University of Oslo, Oslo, Norway, CEDOC, Integrated Pathophysiological Mechanisms Research Group, Nova Medical School, Campo dos Martires da Patria, Lisbon, and Serviço de Imunoalergologia, Centro Hospitalar de Lisboa Central, EPE, Lisbon, Portugal, Regional Ministry of Health of Andalusia, Seville, Spain, Allergy and Asthma Associates of Southern California, Mission Viejo, CA, United States, ASA-Advanced Solutions Accelerator, Clapiers, France, Division of Allergy/Immunology, University of South Florida, Tampa, FL, United States, Celentano pharmacy, Massa Lubrense, Italy, Allergy and Immunology Laboratory, Metropolitan University Hospital, Branquilla, Colombia, Capital Institute of Pediatrics, Chaoyang district, Beijing, China, School of Medicine, University CEU San Pablo, Madrid, Spain, David Tvildiani Medical University-AIETI Highest Medical School, David Tatishvili Medical Center Tbilisi, Georgia, Pulmonolory Research Institute FMBA, Moscow, Russian Federation, GARD Executive Committee, Moscow, Russian Federation, National Heart & Lung Institute, Imperial College, London, United Kingdom, Specialist social worker, Sorrento, Italy, Argentine Federation of Otorhinolaryngology Societies, Buenos Aires, Argentina, Eskisehir Osmangazi University, Medical Faculty, ENT Department, Eskisehir, Turkey, Medicine Department, IRCCS-Azienda Ospedaliera Universitaria San Martino, Genoa, Italy, Universidade Federal da Bahia, Escola de Enfermagem, Brazil, Plateforme Transversale d’Allergologie, Institut du Thorax, CHU de Nantes, Nantes, France, LANUA International Healthcare Consultancy, Northern Ireland, United Kingdom, Innovation and Research Office, Department of Health and Social Solidarity, Autonomous Province of Trento, Italy, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal, ICVS/3B’s, PT Government Associate Laboratory, Braga/Guimarães, Portugal, Guadalarara, Mexico, FIMMG (Federazione Italiana Medici di Medicina Generale), Milan, Italy, UCIBIO, REQUINTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing of University of Porto(Porto4Ageing), Porto, Portugal, IMT Mines Alès, Unversité Montpellier, Alès, France, Department of Medicine, Nova Southeastern University, Davie, University of Miami Dept of Medicine, Miami, FL, United States, ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Planning Group, Brazil, Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester and University Hospital of South Manchester, Manchester, United Kingdom, Medical Consulting Czarlewski, Levallois, France, The Centre for Allergy Research, The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Azienda Provinciale per i Servizi Sanitari di Trento (APSS-Trento), Italy, Department of Internal Medicine, Federal University of Santa Catarina, Trindade, Florianópolis, Santa Catarina, Brazil, Sleep Unit, Department of Neurology, Hôpital Gui-de-Chauliac Montpellier, Inserm U1061, France, Department of Dermatology and Allergy, Technische Universität München, Munich, Germany, ZAUM-Center for Allergy and Environment, Helmholtz Center Munich, Technische Universität München, Munich, Germany, Allergy Division, Chest Disease Department, University Hospital of Strasbourg, Strasbourg, France, AQuAS, Barcelna, Spain, Policlínica Geral do Rio de Janeiro, Rio de Janeiro, Brazil, Social workers oordinator, Sorrento, Italy, Federal University of the State of Rio de Janeiro, School of Medicine and Surgery, Rio de Janeiro, Brazil, Allergology and Immunology Discipline, 'Iuliu Hatieganu' University of Medicine and Pharmacy, Cluj-Napoca, Romania, Department of Medicine, Division of Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada, Laboratoire de Pharmacologie Respiratoire UPRES EA220, Hôpital Foch, Suresnes, Université Versailles Saint-Quentin, Université Paris Saclay, France, Farmacie Dei Golfi Group, Massa Lubrense, Italy, Rangueil-Larrey Hospital, Respiratory Diseases Department, Toulouse, France, University Clinic of Pulmology and Allergy, Medical Faculty Skopje, North Macedonia, Service de Pneumo-Allergologie, Centre Hospitalo-Universitaire de Béni-Messous, Algiers, Algeria, Clinic of infectious, chest diseases, dermatology and allergology, Vilnius University, Vilnius, Lithuania, Allergy and Clinical Immunology National Heart and Lung Institute, Imperial College London, United Kingdom, Guy’s and st Thomas’ NHS Trust, Kings College London, United Kingdom, Pediatric Allergy and Immunology Unit, Children’s Hospital, Ain Shams University, Cairo, Egypt, Department of Computing Science, Umeå University, Sweden and Four Computing Oy, Finland, University of São Paulo Medical School, Sao Paulo, Brazil, Andalusian Agency for Healthcare Quality, Seville, Spain, Global Allergy and Asthma Platform GAAPP, Vienna, Austria, Division of Allergy, Department of Pediatric Medicine-The Bambino Gesù Children’s Research Hospital Holy see, Rome, Italy, Department of Otorhinolaryngology, Amsterdam, University Medical Centres, AMC, Amsterdam, Netherlands, CINTESIS, Center for Research in Health Technologies and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, MEDIDA, Lda, Porto, Portugal, AllergistReims, France, Hospital general regional 1 'Dr Carlos Mc Gregor Sanchez Navarro' IMSS, Mexico City, Mexico, Regional hospital of ISSSTE, Puebla, Mexico, National Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia, Allergy Clinic, National Institute of Respiratory Diseases, Mexico City, Mexico, Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istambul, Turkey, Allergology unit, UHATEM 'NIPirogov', Sofia, Bulgaria, Medical University, Faculty of Public Health, Sofia, Bulgaria, Allergy and Immunology Division, Clinica Ricardo Palma, Lima, Peru, Department of Internal Medicine, section of Allergology, Erasmus MC, Rotterdam, Netherlands, Allergy & Asthma Unit, Hospital San Bernardo Salta, Argentina, Allergy Clinic, Hospital Regional del ISSSTE ‘Lic. López Mateos’, Mexico City, Mexico, Centro Regional de Excelencia CONACYT y WAO en Alergia, Asma e Inmunologia, Hospital Universitario, Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico, Center of Allergy and Immunology, Georgian Association of Allergology and Clinical Immunology, Tbilisi, Georgia, Latvian Association of Allergists, Center of Tuberculosis and Lung Diseases, Riga, Latvia, Federal District Base Hospital Institute, Brasília, Brazil, Institute of Health Policy and Management iBMG, Erasmus University, Rotterdam, Netherlands, University Hospital Olomouc – National eHealth Centre, Czech Republic, Immunology and Allergy Division, Clinical Hospital, University of Chile, Santiago, Chile, Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, Centich: centre d’expertise national des technologies de l’information et de la communication pour l’autonomie, Gérontopôle autonomie longévité des Pays de la Loire, Conseil régional des Pays de la Loire, Centre d’expertise Partenariat Européen d’Innovation pour un vieillissement actif et en bonne santé, Nantes, France, Autonomous University of Baja California, Ensenada, Baja California, Mexico, Department of Paediatrics and Child Health, University College Cork, Cork, Ireland, Hospital General Regional 1 'Dr. Carlos MacGregor Sánchez Navarro' IMSS, Mexico City, Mexico, Université Paris-Sud, Service de Pneumologie, Hôpital Bicêtre, Inserm UMR_S999, Le Kremlin Bicêtre, France, Dipartimento di medicina, chirurgia e odontoiatria, università di Salerno, Italy, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&D and DISMET) Naples, Italy, Libra Foundation, Buenos Aires, Argentina, Medical University of Gdańsk, Department of Allergology, Gdansk, Poland, Airway Disease Infection Section, National Heart and Lung Institute, Imperial College, MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom, Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium, Hallym University College of Medicine, Hallym University Sacred Heart HospitalGyeonggi-do, South Korea, Department of Clinical Immunology, Wrocław Medical University, Poland, Ukrainina Medical Stomatological Academy, Poltava, Ukraine, Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey, Hacettepe University, School of Medicine, Department of Chest Diseases, Immunology and Allergy Division, Ankara, Turkey, Allergy Centre, Tampere University Hospital, Tampere, Finland, First Department of Family Medicine, Medical University of Lodz, Poland, Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Berlin, and Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Germany, Department of Medicine, McMaster University, HealthSciences Centre 3V47, West, Hamilton, ON, Canada, National Research Center, Institute of Immunology, Federal Medicobiological Agency, Laboratory of Molecular immunology, Moscow, Russian Federation, GARD Chairman, Geneva, Switzerland, Allergy & Asthma Center Westend, Berlin, Germany, Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Lodz, Poland, Children’s Hospital and University of Helsinki, Finland, Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Poland, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, Presidente CMMC, Milano, Italy, Head of the Allergy Department of Pedro de Elizalde Children’s Hospital, Buenos Aires, Argentina, University of Medicine and Pharmacy, Hochiminh City, Viet Nam, Federal University of Bahia, Brazil, Sifmed, Milano, Italy, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, Departments of Internal Medicine and Pediatrics (Divisions of Allergy and Immunology), University of Tennessee College of Medicine, Germantown, TN, United States, Scottish Centre for Respiratory Research, Cardiovascular & Diabetes Medicine, Medical Research Institute, Ninewells Hospital, University of Dundee, United Kingdom, Oslo University Hospital, Department of Paediatrics, Oslo, and University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway, Department of Pulmonary Medicine, CHU Sart-Tilman, and GIGA I3 research group, Liege, Belgium, Department of Philosophical, Methodological and Instrumental Disciplines, CUCS, University of Guadalajara, Guadalajara, Mexico, Department of Pulmonary Medicine, Rashid Hospital, Dubai, United Arab Emirates, Biomax Informatics AG, Munich, Germany, Director Gerneral for Health and Social Care, Scottish Government, Edinburgh, United Kingdom, Department of Respiratory Medicine, University of Bratislava, Bratislava, Slovakia, Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Portugal, Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal, Medical center Iskar Ltd Sofia, Bulgaria, Department of Medicine (RCSI), Bon Secours Hospital, Glasnevin, Dublin, Ireland, Kronikgune, International Centre of Excellence in Chronicity Research Barakaldo, Bizkaia, Spain, Division of Clinical Immunology and Allergy, Laboratory of Behavioral Immunology Research, The University of Mississippi Medical Center, Jackson, MS, United States, Tobacco Control Research Centre, Iranian Anti Tobacco Association, Tehran, Iran, Argentine Association of Allergy and Clinical Immunology, Buenos Aires, Argentina, University of Southeast Bahia, Brazil, Allergie-Centrum-Charité at the Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Germany, Maputo Central Hospital--Department of Paediatrics, Mozambique, Veracruz, Mexico, Sachs’ Children and Youth Hospital, Södersjukhuset, Stockholm and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Allergy and Asthma Medical Group and Research Center, San Diego, CA, United States, Department of Physiology, CHRU, University Montpellier, Vice President for Research, PhyMedExp, INSERM U1046, CNRS UMR 9214, France, Croatian Pulmonary Society, Croatia, National Institute of Pneumology M Nasta, Bucharest, Romania, Clinic for Pulmonary Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbian Association for Asthma and COPD, Belgrade, Serbia, Regione Piemonte, Torino, Italy, Col Jardines de Sta Monica, Tlalnepantla, Mexico, National Center for Research in Chronic Respiratory Diseases, Tishreen University School of Medicine, Latakia, Syrian Arab Republic, Department of Public health and health products, Paris Descartes University-Sorbonne Paris Cité, EA 4064 and Paris Municipal Department of social action, childhood, and health, Paris, France, Paris municipal Department of social action, childhood, and health, Paris, France, Lead Respiratory Physician Mater Dei Hospital Malta, Academic Head of Dept and Professor of Medicine University of Malta, Deputy Dean Faculty of Medicine and Surgery University of Medicine, La Valette, Malta, Instituto de Prevision Social IPS HC, Socia de la SPAAI, Tesorera de la SLAAI, Asuncion, Paraguay, Universidade de São Paulo, São Paulo, Brazil, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Germany and CRI-Clinical Research International-Ltd, Hamburg, Germany, General Pathology Institute, Faculty of Medicine, University of Coimbra, Portugal, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Spain, Danish Commitee for Health Education, Copenhagen East, Denmark, Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy, Medical Communications Consultant, MedScript Ltd, Dundalk, Co Louth, Ireland and Honorary Research Fellow, OPC, Cambridge, United Kingdom, General Manager of COFASER-Pharmacy Services Consortium, Salerno, Italy, Scientific Centre of Children’s Health under the MoH, Moscow, Russian National Research Medical University named Pirogov, Moscow, Russian Federation, Dept of Otorhinolaryngology, Medical University of Vienna, AKH, Vienna, Austria, Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary, Die Hautambulanz and Rothhaar study center, Berlin, Germany, Neumología y Alergología Infantil, Hospital La Fe, Valencia, Spain, Center for Health Technology and Services Research-CINTESIS and Department of Internal Medicine, Centro Hospitalar Sao Joao, Porto, Portugal, Caisse d’assurance retraite et de la santé au travail du Languedoc-Roussillon (CARSAT-LR), Montpellier, France, Director of Department of Pharmacy of University of Naples Federico II, Naples, Italy, ENT Department, University Hospital of Kinshasa, Kinshasa, Congo, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia, Medical center 'Research expert', Varna, Bulgaria, National Hospital Organization, Tokyo National Hospital, Tokyo, Japan, Dept of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Dept of Otolaryngology, Nippon Medical School, Tokyo, Japan, Jalisco, Guadalarara, Mexico, Centre Hospitalier Universitaire Pédiatrique Charles de Gaulle, Ouagadougou, Burkina Faso, Dept of Comparative Medicine, Messerli Research Institute of the University of Veterinary Medicine and Medical University, Vienna, Austria, Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic, Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children’s Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children’s Hospital 'P&A Kyriakou,' University of Athens, Athens, Greece, Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea, Respiratory Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy, Allergy and Respiratory Diseases, Ospedale Policlino San Martino-University of Genoa, Italy, Farmacias Holon, Lisbon, Portugal, Department of Pediatrics, Nippon Medical School, Tokyo, Japan, University of Southern Denmark, Kolding, Denmark, Université Grenoble Alpes, Laboratoire HP2, Grenoble, INSERM, U1042 and CHU de Grenoble, France, Allergy Unit, CUF-Porto Hospital and Institute, Center for Research in Health Technologies and information systems CINTESIS, Universidade do Porto, Portugal, Sociologist, municipality area n33, Sorrento, Italy, Centre for empowering people and communites, Dublin, United Kingdom, Société de Pneumologie de Langue Française, Espace francophone de Pneumologie, Paris, France, Département de pédiatrie, CHU de Grenoble, Grenoble, France, Medical School, University of Cyprus, Nicosia, Cyprus, Children’s Hospital Srebrnjak, Zagreb, School of Medicine, University J.J. Strossmayer, Osijek, Croatia, Karl Landsteiner Institute for Clinical and Experimental Pneumology, Hietzing Hospital, Vienna, Austria, University Hospital ‘Sv. Ivan Rilski’', Sofia, Bulgaria, Allergy Diagnostic and Clinical Research Unit, University of Cape Town Lung Institute, Cape Town, South Africa, IML, Milano, Italy, Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom, Observational and Pragmatic Research Institute, Singapore, Singapore, Department of Otorhinolaryngology University of Crete School of Medicine, Heraklion, Greece, European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Brussels, Belgium, Cancun, Quintana Roo, Mexico, LungenClinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany, Department of Medicine, Christian Albrechts University, Airway Research Center North, Member of the German Center for Lung Research (DZL), Kiel, Germany, Department of Nephrology and Endocrinology, Karolinska University Hospital, Stockholm, Sweden, Farmácia São Paio, Vila Nova de Gaia, Porto, Portugal, St Vincent’s Hospital and University of Sydney, Sydney, NSW, Australia, Puebla, Mexico, Serviço de Pneumologia-Hosp das Clinicas UFPE-EBSERH, Recife, Brazil, Universidade Federal de São Paulo, São Paulo, Brazil, Centre of Pneumology, Coimbra University Hospital, Portugal, Polibienestar Research Institute, University of Valencia, Valencia, Spain, Pediatric Allergy and Clinical Immunology, Hospital Angeles Pedregal, Mexico City, Mexico, Getafe University Hospital Department of Geriatrics, Madrid, Spain, Association Asthme et Allergie, Paris, France, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, Primary Care Respiratory Research Unit Institutode Investigación Sanitaria de Palma IdisPa, Palma de Mallorca, Spain, Allergy Unit, Presidio Columbus, Rome, Catholic University of Sacred Heart, Rome and IRCCS Oasi Maria SS, Troina, Italy, Medical University of Graz, Department of Internal Medicine, Graz, Austria, Serviço de Imunoalergologia Hospital da Luz Lisboa, Portugal, Hospital de Clinicas, University of Parana, Brazil, Division of Allergy Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel, Honorary Clinical Research Fellow, Allergy and Respiratory Research Group, The University of Edinburgh, Edinburgh, United Kingdom, Showa University School of Medicine, Tokyo, Japan, Association of Finnish Pharmacies, Finland, Allergy and Clinical Immunology Department, Centro Médico-Docente la, Trinidad and Clínica El Avila, Caracas, Venezuela, Faculty of Medicine, Autnonous University of Madrid, Spain, The Royal National TNE Hospital, University College London, United Kingdom, DIBIMIS, University of Palermo, Italy, Asthma Reference Center, Escola Superior de Ciencias da Santa Casa de Misericordia de Vitoria-Esperito Santo, Brazil, THe Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom, Department of Pediatrics & Child Health, Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada, INSERM, Université Grenoble Alpes, IAB, U 1209, Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, Université Joseph Fourier, Grenoble, France, Sociedad Paraguaya de Alergia Asma e Inmunologı´a, Paraguay, Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil, European Health Futures Forum (EHFF), Dromahair, Ireland, ENT, Aachen, Germany, Kyrgyzstan National Centre of Cardiology and Internal medicine, Euro-Asian respiratory Society, Bishkek, Kyrgyzstan, University Hospital Olomouc, Czech Republic, Department of Paediatric and Adolescent medicine, University Hospital of North Norway, Tromsø, Paediatric Research Group, Deptarment of Clinical Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway, Presidente, IML (Lombardy Medical Initiative), Bergamo, Italy, Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, Public Health Institute of Vilnius University, Vilnius, Lithuania, Universi-dade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, RNSA (Réseau National de Surveillance Aérobiologique), Brussieu, France, The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Canada, Imunoalergologia, Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of Coimbra, Portugal, Depart-ment of ENT, Medical University of Graz, Austria, Campania Region, Division on Pharmacy and devices policy, Naples, Italy, Department of Respiratory Medicine, Hvidovre Hospital & University of Copenhagen, Denmark, Universidade Federal dos Pampas, Uruguaiana, Brazil, Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria, Pneumology and Allergy Department CIBERES and Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Spain, Vilnius University Institute of Clinical Medicine, Clinic of Children’s Diseases, and Institute of Health Sciences, Department of Public Health, Vilnius, Lithuania, Department of Lung Diseases and Clinical Immunology Allergology, University of Turku and Terveystalo allergy clinic, Turku, Finland, PELyon, HESPER 7425, Health Services and Performance Resarch-Université Claude Bernard Lyon, France, Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet and University Hospital, Stockholm, Sweden, Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium, University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy, Pulmonary Unit, Department of Medical Specialties, Arcispedale SMaria Nuova/IRCCS, AUSL di Reggio Emilia, Italy, FILHA, Finnish Lung Association, Helsinki, Finland, Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa, Italy, CNR Institute of Biomedicine and Molecular Immunology 'A Monroy', Palermo, Italy, Medical University, Plovdiv, Bulgaria, Department of Otorhinolaryngology, Plovdiv, Bulgaria, Sotiria Hospital, Athens, Greece, Dept of Otorhinolaryngology, Universitätsklinikum Düsseldorf, Germany, Asthma UK, Mansell street, London, United Kingdom, Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany, Department of Medicine Solna, Immunology and Allergy Unit, Karolinska Institutet and Department of ENT diseases, Karolinska University Hospital, Stockholm, Sweden, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States, International Primary Care Respiratory Group IPCRG, Aberdeen, United Kingdom, Bradford Institute for Health Research, Bradford Royal Infirmary, Bradford, United Kingdom, Allergologyst-Medical College of Medical Faculty, Thracian University, Stara Zagora, Bulgaria, Department of Research, Olmsted Medical Center, Rochester, MN, United States, Cyprus International Institute for Environmental & Public Health in Association with Harvard School of Public Health, Cyprus University of Technology, Limassol, Cyprus, Department of Pediatrics, Hospital 'Archbishop Makarios III', Nicosia, Cyprus, Celal Bayar University Department of Pulmonology, Manisa, Turkey, The Allergy and Asthma Institute, Pakistan, Department of Paediatrics and Child Health, Red Cross Children’s Hospital, and MRC Unit on Child & Adolescent Health, University of Cape Town, Cape Town, South Africa, Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital and Beijing Institute of Otolaryngology, Beijing, China, University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia, Gesundheitsregion KölnBonn-HRCB Projekt GmbH, Kohln, Germany, and Akershus University Hospital, Department of Otorhinolaryngology, Akershus, Norway
- Abstract
mHealth, such as apps running on consumer smart devices is becoming increasingly popular and has the potential to profoundly affect healthcare and health outcomes. However, it may be disruptive and results achieved are not always reaching the goals. Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline using the best evidence-based approach to care pathways suited to real-life using mobile technology in allergic rhinitis (AR) and asthma multimorbidity. Patients largely use over-the-counter medications dispensed in pharmacies. Shared decision making centered around the patient and based on self-management should be the norm. Mobile Airways Sentinel networK (MASK), the Phase 3 ARIA initiative, is based on the freely available MASK app (the Allergy Diary, Android and iOS platforms). MASK is available in 16 languages and deployed in 23 countries. The present paper provides an overview of the methods used in MASK and the key results obtained to date. These include a novel phenotypic characterization of the patients, confirmation of the impact of allergic rhinitis on work productivity and treatment patterns in real life. Most patients appear to self-medicate, are often non-adherent and do not follow guidelines. Moreover, the Allergy Diary is able to distinguish between AR medications. The potential usefulness of MASK will be further explored by POLLAR (Impact of Air Pollution on Asthma and Rhinitis), a new Horizon 2020 project using the Allergy Diary. © 2018 The Author(s).
- Published
- 2018
14. Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America
- Author
-
Patrizia Bonadonna, Kimberly G. Blumenthal, María José Torres, Eric Macy, Annick Barbaud, Pascal Demoly, David A. Khan, Miguel A. Park, Antonino Romano, Gülfem Çelik, Mariana Castells, Werner Aberer, Cristobalina Mayorga, Allergy Unit [Malaga, Spain] (National Network ARADyAL), Hospital Regional Universitario de Málaga [Spain], The Andalusian Center for Nanomedicine and Biotechnology (BIONAND), Allergy Unit [Italy], Presidio Columbus [Italy]-Allergologia - Columbus - Policlinico Gemelli [Italy], Istituto di Ricovero e Cura a Carattere Scientifico [Troina, Italy] (IRCCS), Oasi Maria Santissima Srl [Troina, Italy], Department of Chest Diseases [Ankara, Turkey], Division of Immunology and Allergy [Ankara, Turkey], Ankara University School of Medicine [Turkey]-Ankara University School of Medicine [Turkey], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Department of Internal Medicine [Dallas, TX, USA], University of Texas Southwestern Medical Center [Dallas], Kaiser Permanente, Division of Allergic Diseases [Rochester, MN, USA], Mayo Clinic [Rochester], Division of Rheumatology, Allergy and Immunology [Boston, MA, USA] (Department of Medicine), Massachusetts General Hospital [Boston], Department of Dermatology [Graz, Austria], Medical University Graz, Division of Rheumatology, Immunology and Allergy [Boston, MSA, USA], Brigham and Women's Hospital [Boston], Service de dermatologie et allergologie [CHU Tenon], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Sorbonne Paris Cité (USPC), Allergy Unit [Verona, Italy], Azienda ospedaliera universitaria integrata di Verona [Italy], [Torres,MJ, Mayorga,] Allergy Unit, National Network ARADyAL, IBIMA-Regional University Hospital of Malaga-UMA, Malaga, Spain. [Torres,MJ] BIONAND-Andalusian Centre for Nanomedicine and Biotechnology, Malaga, Spain. [Romano,A] Allergy Unit, Presidio Columbus, Rome, Italy. IRCCS Oasi Maria S.S., Troina, Italy. [Celik,G] Department of Chest Diseases, Division of Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey. [Demoly,P] Hôpital Arnaud de Villeneuve, University Hospital of Montpellier and Sorbonne Universités, UPMC Paris , IPLESP, Equipe EPAR, Paris, France. [Khan,DA] Department of Internal Medicine, Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA. [Macy,E] Kaiser Permanente Health Care Program, San Diego, CA, USA. [Park,M] Mayo Clinic College of Medicine, Division of Allergic Diseases, Mayo Clinic, Rochester, MN , USA. [Blumenthal,K] Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. [Aberer,W] Department of Dermatology, Medical University of Graz, Graz, Austria. [Castells,M] Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MSA, USA. [Barbaud,A] Sorbonne Universities, UPMC Univ Paris, Dermatology and Allergology Department, Tenon Hospital (AP-HP), Paris, France. [Allergy Unit, IBIMA-Regional University Hospital of Malaga-UMA (Pavilion C) Malaga, Spain. [Bonadonna,P] Allergy Unit, Azienda Ospedaliera Universitaria Intergrata of Verona, Verona, Italy., BMC, BMC, Hospital Regional Universitario de Málaga = Regional University Hospital of Malaga [Spain], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)
- Subjects
0301 basic medicine ,Allergy ,[SDV]Life Sciences [q-bio] ,Provocation test ,Presumptive diagnosis ,Review ,Anafilaxia ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,0302 clinical medicine ,Health Care::Population Characteristics::Demography::Ethnic Groups [Medical Subject Headings] ,Clinical history ,Salud pública ,Diagnosis ,Immunology and Allergy ,media_common ,education.field_of_study ,Geographical Locations::Geographic Locations::Americas::North America::United States [Medical Subject Headings] ,Estados Unidos ,Health Care::Population Characteristics::Health::Public Health [Medical Subject Headings] ,3. Good health ,Humanos ,[SDV] Life Sciences [q-bio] ,Europe ,Diseases::Chemically-Induced Disorders::Drug-Related Side Effects and Adverse Reactions::Drug Hypersensitivity [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Evaluation Studies as Topic::Drug Evaluation [Medical Subject Headings] ,Pruebas cutáneas ,IgE ,Drug ,Hipersensibilidad a las drogas ,Europa ,Evaluación de Medicamentos ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,In vitro test ,media_common.quotation_subject ,Concordance ,Immunology ,Population ,Sensitization ,03 medical and health sciences ,Skin test ,medicine ,Hypersensitivity ,Intensive care medicine ,education ,business.industry ,Public health ,T-cells ,Diseases::Immune System Diseases::Hypersensitivity::Hypersensitivity, Immediate::Anaphylaxis [Medical Subject Headings] ,medicine.disease ,United States ,Surgery ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Immunologic Tests::Skin Tests [Medical Subject Headings] ,Grupos étnicos ,030104 developmental biology ,030228 respiratory system ,Drug provocation test ,Geographical Locations::Geographic Locations::Europe [Medical Subject Headings] ,business ,Unit States - Abstract
International audience; AbstractDrug hypersensitivity reactions (DHRs) affect an unknown proportion of the general population, and are an important public health problem due to their potential to cause life-threatening anaphylaxis and rare severe cutaneous allergic reactions. DHR evaluations are frequently needed in both ambulatory and hospital settings and have a complex diagnosis that requires a detailed clinical history and other tests that may include in vitro tests and in vivo procedures such as skin tests and drug provocation tests. Although over the years both European and U.S. experts have published statements on general procedures for evaluating DHRs, a substantial discordance in their daily management exists. In this review, we highlight both the differences and the similarities between the European and U.S. perspectives. While a general consensus exists on the importance of skin tests for evaluating DHRs, concordance between Americans and Europeans exists solely regarding their use in immediate reactions and the fact that a confirmation of a presumptive diagnosis by drug provocation tests is often the only reliable way to establish a diagnosis. Finally, great heterogeneity exists in the application of in vitro tests, which require further study to be well validated.
- Published
- 2016
15. Pediatric Hemophagocytic Syndromes: A Diagnostic and Therapeutic Challenge
- Author
-
Geneviève de Saint Basile, Christine McCusker, Nada Jabado, BMC, Ed., Department of Paediatrics, McGill University = Université McGill [Montréal, Canada]-Montreal Children's Hospital, McGill University Health Center [Montreal] (MUHC)-McGill University Health Center [Montreal] (MUHC), Division of Allergy and Immunology, Developpement Normal et Pathologique du Système Immunitaire, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), McGill University-Montreal Children's Hospital, McGill University Health Center [Montreal, Canada] ( MUHC ) -McGill University Health Center [Montreal, Canada] ( MUHC ), and Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS )
- Subjects
Pulmonary and Respiratory Medicine ,lcsh:Immunologic diseases. Allergy ,Pediatrics ,medicine.medical_specialty ,[SDV.IMM] Life Sciences [q-bio]/Immunology ,business.industry ,Hemophagocytic syndromes ,Immunology ,Review ,General Medicine ,[ SDV.IMM ] Life Sciences [q-bio]/Immunology ,Medicine ,Effective treatment ,Immunology and Allergy ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Identification (biology) ,business ,lcsh:RC581-607 - Abstract
Pediatric hemophagocytic syndrome (HS) is a severe and often fatal clinical disorder. This syndrome is frequently unrecognized, and thus, affected children may receive suboptimal management, leading to an increase in mortality. The purpose of this review is to provide a clinical guide to (1) the recognition of HS based on clinical, biologic, and pathologic features; (2) the identification of the primary cause of HS in a given affected child; and (3) the initiation of effective treatment in a timely manner.
- Published
- 2005
16. The Thr205 phosphorylation site within respiratory syncytial virus matrix (M) protein modulates M oligomerization and virus production
- Author
-
Michael N. Teng, Ralph A. Tripp, Eran Bacharach, Reena Ghildyal, Goedele N. Maertens, Kim C. Tran, Monika Bajorek, David A. Jans, Leon Caly, Section of Virology - Faculty of Medicine, Imperial College London, Department of Biochemistry and Molecular Biology, Mayo Clinic, Division of Allergy and Immunology - Department of Internal Medicine, University of South Florida [Tampa] (USF), Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia [USA], Department of Cell Research and Immunology, Tel Aviv University [Tel Aviv], Centre for Research in Therapeutic Solutions, Faculty of ESTeM, University of Canberra, University of South Florida, and NIH AI081977
- Subjects
[SDV]Life Sciences [q-bio] ,viruses ,Immunology ,Mutant ,Blotting, Western ,Biology ,Recombinant virus ,medicine.disease_cause ,Real-Time Polymerase Chain Reaction ,Virus Replication ,Microbiology ,Virus ,Viral Matrix Proteins ,Microscopy, Electron, Transmission ,Virology ,Chlorocebus aethiops ,medicine ,Animals ,Humans ,Phosphorylation ,Casein Kinase II ,Vero Cells ,DNA Primers ,Infectivity ,Mutation ,Viral matrix protein ,L-Lactate Dehydrogenase ,Structure and Assembly ,3. Good health ,Respiratory Syncytial Viruses ,Viral replication ,Insect Science ,Chromatography, Gel ,Protein Multimerization - Abstract
Human respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia in infants and the elderly worldwide; however, there is no licensed RSV vaccine or effective drug treatment available. The RSV matrix (M) protein plays key roles in virus assembly and budding, but the protein interactions that govern budding of infectious virus are not known. In this study, we focus on M protein and identify a key phosphorylation site (Thr205) in M that is critical for RSV infectious virus production. Recombinant virus with a nonphosphorylatable alanine (Ala) residue at the site was markedly attenuated, whereas virus with a phosphomimetic aspartate (Asp) resulted in a nonviable virus which could only be recovered with an additional mutation in M (serine to asparagine at position 220), strongly implying that Thr205 is critical for viral infectivity. Experiments in vitro showed that mutation of Thr205 does not affect M stability or the ability to form dimers but implicate an effect on higher-order oligomer assembly. In transfected and infected cells, Asp substitution of Thr205 appeared to impair M oligomerization; typical filamentous structures still formed at the plasma membrane, but M assembly during the ensuing elongation process seemed to be impaired, resulting in shorter and more branched filaments as observed using electron microscopy (EM). Our data thus imply for the first time that M oligomerization, regulated by a negative charge at Thr205, may be critical to production of infectious RSV. IMPORTANCE We show here for the first time that RSV M's role in virus assembly/release is strongly dependent on threonine 205 (Thr205), a consensus site for CK2, which appears to play a key regulatory role in modulating M oligomerization and association with virus filaments. Our analysis indicates that T205 mutations do not impair M dimerization or viruslike filament formation per se but rather the ability of M to assemble in ordered fashion on the viral filaments themselves. This appears to impact in turn upon the infectivity of released virus rather than on virus production or release itself. Thus, M oligomerization would appear to be a target of interest for the development of anti-RSV agents; further, the recombinant T205-substituted mutant viruses described here would appear to be the first RSV mutants affected in viral maturation to our knowledge and hence of considerable interest for vaccine approaches in the future.
- Published
- 2014
17. Assessment of disease control in allergic rhinitis
- Author
-
Moises A. Calderon, Thierry Haddad, Bertrand Delaisi, Thomas B. Casale, Jean Jacques Braun, Isabella Annesi-Maesano, Elie Serrano, Olivier Malard, Pascal Demoly, Florence Trebuchon, Glenis Scadding, Pharmacoepidemiologie et évaluation de l'impact des produits de santé sur les populations, Université Bordeaux Segalen - Bordeaux 2-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Section of Allergy and Clinical Immunology, Imperial College London-Royal Brompton Hospital, Division of Allergy and Immunology, Department of Medicine-Creighton University, Rhinology Department, Royal National Throat, Nose and Ear Institute, Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'ORL et chirurgie cervico-faciale, CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Service de gastro-entérologie, mucoviscidose, pneumologie et nutrition[Debré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Service de dermatologie et allergologie [CHU Tenon], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'oto-rhino-laryngologie, Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Allergologie, Cabinet d'Allergologie, Oto - Rhino - Laryngologie (O.R.L.) et chirurgie cervico-faciale [Toulouse], CHU Toulouse [Toulouse]-Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service ORL, otoneurologie et ORL pédiatrique [CHU Toulouse], Pôle Céphalique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), BMC, Ed., CHU Tenon [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Pediatrics ,[SDV.IMM] Life Sciences [q-bio]/Immunology ,Immunology ,MEDLINE ,Alternative medicine ,Review ,Allergic rhinitis ,03 medical and health sciences ,0302 clinical medicine ,Disease severity ,Disease control ,medicine ,Immunology and Allergy ,Respiratory function ,030212 general & internal medicine ,Psychiatry ,Control (linguistics) ,Asthma ,ARIA ,business.industry ,Questionnaire ,medicine.disease ,Rescue medication ,Classification ,GINA ,3. Good health ,030228 respiratory system ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,business - Abstract
International audience; The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative has had a significant impact, by raising awareness of allergic rhinitis (AR) and improving the diagnosis and treatment of AR sufferers. ARIA classifies the severity of AR as "mild" or "moderate/severe" on the basis of "yes"/"no" answers to four questions. This two-point classification has been criticized as providing little guidance on patient management; patients with "mild" AR are unlikely to consult a physician, whereas the group of patients with "moderate/severe" seen by specialists is heterogeneous. These perceived shortcomings have prompted attempts to improve the ARIA classification or, by analogy with the Global Initiative for Asthma (GINA), adopt approaches based on "disease control" in AR. Even though "disease severity", "disease control" and "responsiveness to treatment" are different (albeit related) metrics, they are not mutually exclusive. Currently, there is no single, accepted definition, but we propose that "disease control" in AR can combine (i) measurements of the severity and/or frequency of daily or nocturnal symptoms, (ii) impairments in social, physical, professional and educational activities, (iii) respiratory function monitoring and (iv) exacerbations (e.g. unscheduled medical consultations and rescue medication use). Although control-based classifications have a number of limitations (e.g. their dependence on treatment compliance and the patient's psychological status), these instruments could be used as an adjunct to the ARIA severity classification and regional practice parameters. Here, we assess the strengths and weaknesses of the current two-level ARIA classification, analyze published proposals for its modification and review the literature on instruments that measure AR control. We conclude that there is a need for research in which severity is compared with control in terms of their effects on patient management.
- Published
- 2013
18. Severe Chronic Allergic (and related) Diseases: a uniform approach- a MeDALL- GA(2)LEN-ARIA Position Paper
- Author
-
WHO Collaborating Center for Asthma, Rhinitis, Bousquet, J, Anto, Jm, Demoly, P, Schünemann, Hj, Togias, A, Akdis, M, Auffray, C, Bachert, C, Bieber, T, Bousquet, Pj, Carlsen, Kh, Casale, Tb, Cruz, Aa, Keil, T, Lodrup Carlsen KC, Maurer, M, Ohta, K, Papadopoulos, Ng, Roman Rodriguez, M, Samolinski, B, Agache, I, Andrianarisoa, A, Ang, Cs, Annesi Maesano, I, Ballester, F, Baena Cagnani CE, Basagaña, X, Bateman, Ed, Bel, Eh, Bedbrook, A, Beghe', Bianca, Beji, M, Ben Kheder, A, Benet, M, Bennoor, Ks, Bergmann, Kc, Berrissoul, F, Bindslev Jensen, C, Bleecker, Er, Bonini, S, Boner, Al, Boulet, Lp, Brightling, Ce, Brozek, Jl, Bush, A, Busse, Ww, Camargos, Pa, Canonica, Gw, Carr, W, Cesario, A, Chen, Yz, Chiriac, Am, Costa, Dj, Cox, L, Custovic, A, Dahl, R, Darsow, U, Didi, T, Dolen, Wk, Douagui, H, Dubakiene, R, El Meziane, A, Fonseca, Ja, Fokkens, Wj, Fthenou, E, Gamkrelidze, A, Garcia Aymerich, J, Gerth van Wijk, R, Gimeno Santos, E, Guerra, S, Haahtela, T, Haddad, H, Hellings, Pw, Hellquist Dahl, B, Hohmann, C, Howarth, P, Hourihane, Jo, Humbert, M, Jacquemin, B, Just, J, Kalayci, O, Kaliner, Ma, Kauffmann, F, Kerkhof, M, Khayat, G, Koffi N'Goran, B, Kogevinas, M, Koppelman, Gh, Kowalski, Ml, Kull, I, Kuna, P, Larenas, D, Lavi, I, Le, Lt, Lieberman, P, Lipworth, B, Mahboub, B, Makela, Mj, Martin, F, Martinez, Fd, Marshall, Gd, Mazon, A, Melen, E, Meltzer, Eo, Mihaltan, F, Mohammad, Y, Mohammadi, A, Momas, I, Morais Almeida, M, Mullol, J, Muraro, A, Naclerio, R, Nafti, S, Namazova Baranova, L, Nawijn, Mc, Nyembue, Td, Oddie, S, O'Hehir, Re, Okamoto, Y, Orru, Mp, Ozdemir, C, Ouedraogo, Gs, Palkonen, S, Panzner, P, Passalacqua, G, Pawankar, R, Pigearias, B, Pin, I, Pinart, M, Pison, C, Popov, Ta, Porta, D, Postma, Ds, Price, D, Rabe, Kf, Ratomaharo, J, Reitamo, S, Rezagui, D, Ring, J, Roberts, R, Roca, J, Rogala, B, Romano, A, Rosado Pinto, J, Ryan, D, Sanchez Borges, M, Scadding, Gk, Sheikh, A, Simons, Fe, Siroux, V, Schmid Grendelmeier PD, Smit, Ha, Sooronbaev, T, Stein, Rt, Sterk, Pj, Sunyer, J, Terreehorst, I, Toskala, E, Tremblay, Y, Valenta, R, Valeyre, D, Vandenplas, O, van Weel, C, Vassilaki, M, Varraso, R, Viegi, G, Wang, Dy, Wickman, M, Williams, D, Wöhrl, S, Wright, J, Yorgancioglu, A, Yusuf, Om, Zar, Hj, Zernotti, Me, Zidarn, M, Zhong, N, Zuberbier, T., Beghe', B., Fthenou, E., Boudier, Anne, Hôpital Arnaud de Villeneuve [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), IMIM-Hospital del Mar, Generalitat de Catalunya, Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, CIBER Epidemiologia y Salud Publica, CIBER de Epidemiología y Salud Pública (CIBERESP), Universitat Pompeu Fabra [Barcelona] (UPF), WHO Collaborating Center for Asthma and Rhinitis, Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Pharmacoepidemiologie et évaluation de l'impact des produits de santé sur les populations, Université Bordeaux Segalen - Bordeaux 2-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Clinical Epidemiology and Biostatistics and Medicine, McMaster University [Hamilton, Ontario], National Institute of Allergy and Infectious Diseases [Bethesda] (NIAID-NIH), National Institutes of Health [Bethesda] (NIH), Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Génomique fonctionnelle et biologie systémique pour la santé, Institut des Sciences Biologiques du CNRS, Upper Airway Research Laboratory (URL), Ghent University Hospital, Department of Dermatology and Allergy, VU University Medical Center [Amsterdam], Department of Paediatrics, University of Oslo (UiO)-Oslo University Hospital [Oslo], Division of Allergy and Immunology, Department of Medicine, Creighton University, ProAR - FMB, Federal University of Bahia School of Medicine, Epidemiology and Health Economics, Instittute of Social Health-Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Department of Dermatology, Medical School-Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, Allergy Department, 2nd Pediatric Clinic, Son Pisa Primary Care Centre, IB-Salut Balearic Health Service, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw - Poland-Faculté de Pharmacie de Paris, Department of Allergy and Clinical Immunology, Faculty of Medicine-Transylvania University, Public Hospital Medical Service, Ministry of Health [Mozambique], Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Public Health Research (CSISP), University of Valencia, Respiratory Medicine, Università degli studi di Genova = University of Genoa (UniGe)-School of Specialization, Faculty of Medicine, Catholic University, Health Sciences Faculty, University of Cape Town, Department of Pulmonology, University of Amsterdam [Amsterdam] (UvA)-Academic Medical Centre, Divisions of Human Genetics Infection, Inflammation and Repair, University of Southampton-School of Medicine, Service de Pneumologie Allergologie, Hôpital La Rabta [Tunis], Service de Pneumologie, Hôpital Abderrahmen Mami, National Asthma Centre, National Institute of Diseases of the Chest and Hospital (NIDCH), Pneumologie / Anesthésie - réanimation / Oxygénothérapie, Hôpital AKS Phnom Penh-Hôpital Provincial de Siemreap, Department of Dermatology and Allergy Center, Odense University Hospital, Center for Genomics and Personalized Medicine, Wake Forest University, Institute of Neurobiology and Molecular Medicine, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II = Università degli studi di Napoli Federico II, Università degli studi di Verona = University of Verona (UNIVR), Institut de cardiologie et de pneumologie, Université Laval [Québec] (ULaval)-Centre Hospitalier de Laval (CH Laval), Department of Respiratory Medicine and Thoracic Surgery, University of Leicester-Institute for Lung Health, Department of Paediatric Respiratory Medicine, Imperial College London-Royal Brompton Hospital-National Heart and Lung Institute [UK], Department of Medicine, University of Wisconsin School of Medicine and Public Health, Department of Pediatrics, Universidade Federal de Minas Gerais [Belo Horizonte] (UFMG)-Medical School, Allergy & Respiratory Diseases, Università degli studi di Genova = University of Genoa (UniGe)-Department of Internal Medicine (DIMI), Allergy & Asthma Associates, University of California [Irvine] (UC Irvine), University of California (UC)-University of California (UC), Deputy Scientific Director, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Department of Thoracic Surgery, Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), National Cooperative Group of Pediatric Research on Asthma, Asthma Clinic and Education Center of the Capital Institute of Pediatrics, Service des Premiers Soins, Université Montpellier 1 (UM1), Osteopathic College of Medicine, Nova Southeastern University (NSU), Respiratory Research Group, University of Manchester [Manchester]-School of Translational Medicine, Department of Respiratory Diseases, Aarhus University Hospital, Department of Dermatology and Allergy Biederstein, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Service de pneumologie, Centre hospitalier de la région d'Annecy, Service de pneumo-allergologie, Centre Hospitalo-Universitaire de Béni-Messous, Allergy Centre, Vilnius University Antakalnis Hospital, Société Marocaine des Maladies Respiratoires, Centre of Respiratory Diseases and Allergy-Centre commercial Nadia, Allergy Division, Hospital S. João-Centre for Research in Health Technologies and Information Systems (CINTESIS)-Biostatistics and Medical Informatics Department-Porto University Medical School, Department of Otorhinolaryngology, Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA)-University of Amsterdam [Amsterdam] (UvA), Department of Social Medicine, University of Crete [Heraklion] (UOC)-Faculty of Medicine, Health Care, Minister Of Labour-Ministry of Labor, Health and Social Affairs, Section of Allergology, Erasmus Medical Centre, Epidemiology and Biostatistics Division, University of Arizona-Associate Research Scientist, Respiratory Sciences-Arizona Respiratory Center, Helsinki University Hospital-Skin and Allergy Hospital, Centre Hospitalier de Bigorre [Tarbes]-Association Franco-Libanaise de Pneumologie (AFLP), Department of Otorhinolaryngology, Head, and Neck Surgery, University Hospital Leuven, Engineering and the Environment, University of Southampton, Paediatrics and Child Health, University College Cork (UCC), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Antoine Béclère [Clamart], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de l'Asthme et des Allergies [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Pediatric Allergy and Asthma Unit, Ihsan Dogramaci Children's Hospital-Hacettepe University School of Medicine, Institute for Asthma and Allergy, George Washington University Medical School, Department of Epidemiology, University of Groningen [Groningen]-University Medical Center Groningen [Groningen] (UMCG)-Groningen Research Institute for Asthma and COPD (GRIAC), Université Saint-Joseph de Beyrouth (USJ)-Faculté de Médecine-Hôtel-Dieu de France, Service des Maladies Respiratoires, CHU de Cocody-UFR des Sciences Médicales, Pediatric Pulmonology, Allergology & Epidemiology, University of Groningen [Groningen]-University Medical Center Groningen [Groningen] (UMCG)-Beatrix Children's Hospital-Groningen Research Institute for Asthma and COPD, Department of Clinical Immunology and Allergy, Medical University of Łódź (MUL)-Faculty ot Medicine, Centre for Allergy Research, Karolinska Institutet [Stockholm], Department of Clinical Science and Education, Division of Internal Medicine, Asthma and Allergy, Medical University of Łódź (MUL)-Barlicki University Hospital, Hospital Medica Sur, Physiology Department, University of Medicine and Pharmacy, Division of Allergy Immunology, Department of Medicine-The University of Tennessee Health Science Center [Memphis] (UTHSC), university of dundee asthma - allergic rhinitis - COPD - beta-2-adrenoceptor, University of Dundee, Pulmonary and allergy unit, American University of Sharjah-Rashid Hospital-Dubai Health Authority (DHA), Association Franco-Vietnamienne de Pneumologie (AFVP), Centre Hospitalier de Compiègne (CHC), Arizona Respiratory Center, Department of Medicine, Clinical Immunology and Allergy, University of Mississippi Medical Center (UMMC), Institute of Environmental Medicine, Karolinska Institutet [Stockholm]-Karolinska University Hospital [Stockholm]-Astrid Lindgren Children's Hospital, Allergy & Asthma Medical Group & Research Center, University of California [San Diego] (UC San Diego), Pneumology Department, Marius Nasta Institute of Pneumology, Department of Internal Medicine, Tishreen University School of Medicine, Association Franco-Marocaine de Pathologie Thoracique (AFMAPATH), Collège National des Pneumologues Marocains, Epidémiologie Environnementale : Impact Sanitaire des Pollutions (EA 4064), Université Paris Descartes - Paris 5 (UPD5), Immunoallergy Department, Hospital CUF Descobertas, Rhinology Unit & Smell Clinic, Universitat de Barcelona (UB)-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Department of Medicine-Hospital Clinic-ENT Department, Allergy Unit, Università degli Studi di Padova = University of Padua (Unipd)-Department of Paediatrics, Section of Otolaryngology-Head & Neck Surgery (OHNS), University of Chicago, Clinique des maladies respiratoires, centre hospitalo-universitaire Mustapha Pacha d'Alger (CHUMA), Scientific Center for Children's Health, Russian Academy of Medical Sciences (RAMS), Laboratory of Allergology and Pulmonary Diseases, University of Groningen [Groningen]-University Medical Center Groningen [Groningen] (UMCG)-Department of Pathology and Medical Biology-GRIAC Research Institute, ENT Department, University of Kinshasa (UNIKIN), Bradford Neonatology, Bradford Teaching Hospitals NHS Foundation Trust-Bradford Institute for Health Research, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital-Monash University Building, AMREP, Chiba University Hospital, Asthme Rhinite allergique, Pharmacie, Division of Pediatric Allergy and Immunology, marmara university, Pédiatrie, Centre Hospitalier National Pédiatrique Charles de Gaulle (CHNP-CDG), European Federation of Allergy (EFA), Airways Diseases Patients' Associations, Department of Allergology and Clinical Immunology, Charles University [Prague] (CU)-Medical Faculty in Pilsen, Immunopharmacology, Nippon Medical School-Medical Research Council Clinical, Laboratoire du Sommeil et de l'Effort, Société de Pneumologie de Langue Française (SPLF)-Clinique St George, Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de bioénergétique fondamentale et appliquée (LBFA), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinic of Allergy and Asthma, Medical University Sofia-Alexander's University Hospital, Regional Health Service - Lazio, Primary Care Respiratory Medicine, University of Aberdeen-Department of General Practice and Primary Care-General Practice Airways Group (GPIAG), Department of Pulmonary Medicine, Leiden University Medical Center (LUMC), Pneumalgia, Centre Hospitalier Regional-Espace Francophone de Pneumologie (EFP)-Société de Pneumologie de l'Océan Indien (SPOI), Association Franco-Algérienne de Pneumologie (AFAP), Espace Francophone de pneumologie de la SPLF, Department of Pneumology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clínic de Barcelona-Institut Clínic del Tórax (ICT)-CIBER de Enfermedades Respiratorias (CIBERES)-University of Barcelona, Allergology and Clinical Immunology, Medical University of Silesia (SUM)-Chair and Clinical Department of Internal Diseases, UCSC-Allergy Unit, Complesso Integrato Columbus-Department of Internal Medicine and Geriatrics, Hospital da Luz, Medical Centre, Woodbrook Medical Centre, Research Fellow, University of Aberdeen-Department of General Practice, Centro Médico Docente La Trinidad, Department of Pharmacology, University College of London [London] (UCL)-The Royal National Throat, Nose and Ear Hospital, Primary Care Research & Development, University of Edinburgh-Centre for Population Health Sciences, Section of Allergy & Clinical Immunology, University of Manitoba [Winnipeg]-Department of Pediatrics & Child Health, Allergy Unit - Department of Dermatology, Julius Center for Health Sciences and Primary Care, University Medical Center [Utrecht], National Centre of Cardiology and Internal Medicine, Ministry of Health Kyrgyz Republic, School of Medicine, Pontifícia Universidade Católica, Department of ENT and Pediatrics, Finnish Institute of Occupational Health, Department of Obstetrics and Gynaecology, Université Laval [Québec] (ULaval)-Faculty of Medicine, Christian Doppler Laboratory for Allergy Research, Medizinische Universität Wien = Medical University of Vienna-Division of Immunopathology-Department of Pathophysiology and Allergy Research-Center for Pathophysiology, Infectiology and Immunology, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Department of Chest Medicine, Mont-Godinne Hospital-Catholic University of Louvain de Mont-Godinne, Department of Primary and Community Care, Radboud University Medical Center [Nijmegen], Epidemiology Unit, National Research Council (CNR)-Institute of Biomedicine and Molecular Immunology (IBIM), Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Department of Otolaryngology, National University of Singapore (NUS)-Yong Loo Lin School of Medicine, Karolinska Institutet [Stockholm]-Sachs' Children's Hospital, GLP Analytical Facility, School of Pharmacy, Department of Dermatology Division of Immunology, Allergy and Infectious Diseases (DIAID), Medical University of Vienna (MUW), Celal Bayar University School of Medicine, Allergy and Asthma Clinics, The Allergy and Asthma Institute, Department of Paediatrics and Child Health, Respiratory and Allergic Diseases, University Clinic of Respiratory and Allergic Diseases Golnik, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Diseases-Guangzhou Medical College, Secretary General of the Global Allergy and Asthma European Network (GA2LEN), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], In collaboration with the WHO Collaborating Center for Asthma and Rhinitis, University of Genoa (UNIGE)-School of Specialization, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II, University of Verona (UNIVR), Medical School-Federal University of Minas Gerais, University of Genoa (UNIGE)-Department of Internal Medicine (DIMI), University of California [Irvine] (UCI), University of California-University of California, Catholic University Rome, University of Amsterdam [Amsterdam] (UvA)-Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), Centre Hospitalier de Bigorre (Tarbes)-Association Franco-Libanaise de Pneumologie (AFLP), CUF-Descobertas Hospital, Universita degli Studi di Padova-Department of Paediatrics, Medical Faculty in Pilsen-Charles University in Prague - the First Faculty of Medicine, Centro Medico-Docente La Trinidad, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]-Instittute of Social Health, Department of Internal Medicine (DIMI)-University of Genoa (UNIGE), Medical University of Silesia-Chair and Clinical Department of Internal Diseases, Dermatology, Internal Medicine, Immunology, Hôpital Arnaud de Villeneuve, Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Centre de recherche en épidémiologie et santé des populations ( CESP ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Center for Research in Environmental Epidemiology ( CREAL ), Universitat Pompeu Fabra [Barcelona]-Catalunya ministerio de salud, Universitat Pompeu Fabra [Barcelona], WHO(OMS), Université Bordeaux Segalen - Bordeaux 2-Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), National Institute of Allergy and Infectious Diseases [Bethesda], National Institutes of Health ( NIH ), Swiss Institute of Allergy and Asthma Research ( SIAF ), University of Zürich [Zürich] ( UZH ), Upper Airway Research Laboratory ( URL ), University Medical Center, University of Oslo ( UiO ) -Oslo University Hospital, Charite-Universitatsmedizin Berlin [Berlin]-Instittute of Social Health, Medical School-Charité - University Medicine Berlin, Medical University of Warsaw-Faculté de Pharmacie de Paris, Ministry of Health, Epidémiologie des maladies infectieuses et modélisation ( ESIM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Center for Public Health Research ( CSISP ), University of Genoa ( UNIGE ) -School of Specialization, University of Amsterdam [Amsterdam] ( UvA ) -Academic Medical Centre, University of Southampton [Southampton]-School of Medicine, Hôpital La Rabta [Tunis), Wake Forest University Health Sciences, CNR, Rome, Italy and Department of Medicine-Second University of Naples, Università degli Studi di Verona, Université Laval-l'Hôpital Laval, Imperial College London-Royal Brompton Hospital-National Heart and Lung Institute, University of Genoa ( UNIGE ) -Department of Internal Medicine (DIMI), Southern California Research, Université Montpellier 1 ( UM1 ), Nova Southeastern University, Technische Universität München [München] ( TUM ), Academic Medical Center [Amsterdam] ( AMC ), University of Amsterdam [Amsterdam] ( UvA ) -University of Amsterdam [Amsterdam] ( UvA ), University of Crete ( UOC ) -Faculty of Medicine, University of Southampton [Southampton], UUniversity College Cork - National University of Ireland, Cork (UCC), Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Antoine Béclère, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Trousseau [APHP], University of Groningen [Groningen]-University Medical Center Groningen-Groningen Research Institute for Asthma and COPD (GRIAC), Université Saint-Joseph de Beyrouth ( USJ ) -Faculté de Médecine-Hôtel-Dieu de France, University of Groningen [Groningen]-University Medical Center Groningen-Beatrix Children's Hospital-Groningen Research Institute for Asthma and COPD, Medical University of Łódź ( MUL ) -Faculty ot Medicine, Medical University of Łódź ( MUL ) -Barlicki University Hospital, Department of Medicine-University of Tennessee College for Medicine, Association Franco-Vietnamienne de Pneumologie ( AFVP ), University of Mississippi Medical Center, University of California [San Diego] ( UC San Diego ), Association Franco-Marocaine de Pathologie Thoracique ( AFMAPATH ), Epidémiologie Environnementale : Impact Sanitaire des Pollutions ( EA 4064 ), Université Paris Descartes - Paris 5 ( UPD5 ), Universitat de Barcelona ( UB ) -Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Department of Medicine-Hospital Clinic-ENT Department, Section of Otolaryngology-Head & Neck Surgery ( OHNS ), University of Groningen [Groningen]-University Medical Center Groningen-Department of Pathology and Medical Biology-GRIAC Research Institute, University Hospital of Kinshasa, European Federation of Allergy ( EFA ), Institut d'oncologie/développement Albert Bonniot de Grenoble ( INSERM U823 ), Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Bioenergétique fondamentale et appliquée ( LBFA ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Department of General Practice and Primary Care-General Practice Airways Group (GPIAG)-University of Aberdeen, Association Franco-Algérienne de Pneumologie ( AFAP ), Department of General Practice-University of Aberdeen, University College of London [London] ( UCL ) -The Royal National Throat, Nose and Ear Hospital, University Medical Center Utrecht, Faculty of Medicine-Laval University [Québec], Medical University of Vienna-Division of Immunopathology-Department of Pathophysiology and Allergy Research-Center for Pathophysiology, Infectiology and Immunology, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Avicenne, National University of Singapore ( NUS ) -Yong Loo Lin School of Medicine, Department of Dermatology Division of Immunology, Allergy and Infectious Diseases ( DIAID ), Secretary General of the Global Allergy and Asthma European Network ( GA2LEN ), Network of Excellence, Charité - Universitätsmedizin Berlin, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK (BIHR), Universiteit Leiden-Universiteit Leiden, and Medizinische Universität Wien = Medical University of Vienna
- Subjects
MESH: Asthma ,severity ,MESH: Comorbidity ,Comorbidity ,Severity of Illness Index ,urticaria ,MESH : Chronic Disease ,MESH: Practice Guidelines as Topic ,MESH : Dermatitis, Atopic ,MESH: Urticaria ,risk ,216-31 [Rhinitis ,atopy ,allergen Int Arch Allergy Immunol. 2012,158(3)] ,atopic dermatitis ,MESH : Rhinitis ,MESH: Rhinitis ,[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie ,Effective primary care and public health [NCEBP 7] ,Immunoglobulin E - Asthma - Rhinitis - Rhinosinusitis - Urticaria - Atopic dermatitis ,MESH : Practice Guidelines as Topic ,Practice Guidelines as Topic ,MESH : Comorbidity ,MESH : Severity of Illness Index ,IgE ,MESH: Sinusitis ,MESH : Urticaria ,MESH: Hypersensitivity ,macromolecular substances ,MESH : Asthma ,Dermatitis, Atopic ,rhinitis ,SDG 3 - Good Health and Well-being ,MESH: Dermatitis, Atopic ,MESH: Severity of Illness Index ,Hypersensitivity ,Humans ,Sinusitis ,rhinosinusitis ,MESH : Hypersensitivity ,MESH: Humans ,MESH: Chronic Disease ,MESH : Humans ,Asthma ,Atopic dermatitis ,Immunoglobulin E ,Rhinitis ,Rhinosinusitis ,Urticaria ,asthma ,allergy ,MESH : Sinusitis ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Chronic Disease ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,control - Abstract
Concepts of disease severity, activity, control and responsiveness to treatment are linked but different. Severity refers to the loss of function of the organs induced by the disease process or to the occurrence of severe acute exacerbations. Severity may vary over time and needs regular follow-up. Control is the degree to which therapy goals are currently met. These concepts have evolved over time for asthma in guidelines, task forces or consensus meetings. The aim of this paper is to generalize the approach of the uniform definition of severe asthma presented to WHO for chronic allergic and associated diseases (rhinitis, chronic rhinosinusitis, chronic urticaria and atopic dermatitis) in order to have a uniform definition of severity, control and risk, usable in most situations. It is based on the appropriate diagnosis, availability and accessibility of treatments, treatment responsiveness and associated factors such as comorbidities and risk factors. This uniform definition will allow a better definition of the phenotypes of severe allergic (and related) diseases for clinical practice, research (including epidemiology), public health purposes, education and the discovery of novel therapies. Copyright (C) 2012 S. Karger AG, Basel
- Published
- 2012
19. Global Incidence and Prevalence of Chronic Rhinosinusitis: A Systematic Review.
- Author
-
Min HK, Lee S, Kim S, Son Y, Park J, Kim HJ, Lee J, Lee H, Smith L, Rahmati M, Kang J, Papadopoulos NG, Cho SH, Hahn JW, and Yon DK
- Abstract
Objective: Data on the global prevalence of chronic rhinosinusitis (CRS) is significantly varied and limited across countries and over time. Therefore, we aimed to conduct a comprehensive investigation into the global, regional, and national burden of CRS from the years 1980 to 2021, as well as identify those factors that influence levels of such burden., Design: We conducted a systematic review and meta-analysis of general population-based observational studies focusing on CRS. We calculated pooled estimates of CRS prevalence and incidence with 95% confidence intervals (CIs). Subgroup analyses were conducted stratifying by sex, age cohorts, geographic regions, smoking status, obesity, and comorbid conditions., Data Sources: PubMed/MEDLINE, EMBASE, CINAHL, Google Scholar, and Cochrane databases., Eligibility Criteria for Selection: We included general population-based observational studies on CRS published from database inception through October 20, 2023., Results: A total of 28 eligible studies, encompassing more than 237 million participants and 11,342,923 patients with CRS from 20 countries across four continents, were included in the analysis. Global pooled prevalence of CRS and CRS with nasal polyps (CRSwNP) was found to be 8.71% (95% CI, 6.69-11.33; number of studies, 20) and 0.65% (95% CI, 0.56-0.75; number of studies, 4), respectively. The prevalence of CRS was greater in Europe compared with North America, South America, and Asia; adults compared with children; smokers compared with never-smoker; those with obesity compared with normal weight; and those with comorbidities such as asthma, diabetes mellitus, eczema, and nasal septal deviation. Pooled prevalence of CRS increased from 1980 to 2020 (1980-2000: 4.72%; 95% CI, 2.12-10.49; 2014-2020: 19.40%; 95% CI, 12.12-31.07). Similar patterns were observed in CRS incidence., Conclusions: Our study provides valuable insights into CRS prevalence and incidence across diverse demographic and clinical factors, highlighting its increasing global burden. The reported prevalence of CRS varies internationally, and may be increasing over time. To enhance data quality and comparability, standardization of reporting methodologies is imperative., Systematic Review Registration: PROSPERO (registration no. CRD42024527805)., (© 2024 John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
20. Guidance for the evaluation by payors of claims submitted using Current Procedural Terminology codes 95165, 95115, and 95117.
- Author
-
Meadows JA, Gross GN, Wasan AN, Baker DP, Patterson A, Puchalski R, Nanda A, Lucas J, Sublett JW, and Williams PV
- Published
- 2024
- Full Text
- View/download PDF
21. Human FCHO1 deficiency - Review of the Literature and Additional Two Cases.
- Author
-
Özdemiral C, Yaz I, Esenboga S, Nabiyeva Cevik N, Bildik HN, Kilic M, Tezcan I, and Cagdas D
- Abstract
F-BAR domain only protein 1(FCHO1) contributes as a critical component to an essential cellular process, clathrin-mediated endocytosis(CME). CME involves cellular membrane invagination followed by cargo protein recruitment and adaptor protein assembly to form endocytic vesicles, maintains several cellular functions, such as signaling, differentiation, nutrition, absorption, and secretion. We aimed to determine the clinical/immunological findings in FCHO1 deficiency to generate appropriate medical approach. We present clinical/immunological/genetic findings of two FCHO1 deficiency patients together with recently reported 17 patients. We found two different variants in the patients, one previously defined and one novel homozygous mutation(c.306C>A(p.Tyr102Ter)). Recurrent sinopulmonary infections occurred in all patients, with viral(63.1%) and fungal(52.6%) infections frequently reported. Lymphopenia and CD4+T cell lymphopenia are present in 77.7%(14/18) and 100% of patients, respectively. CD8+ T cell number is low in half. Hypogammaglobulinemia and low IgM are present in 83.3%(15/18) and 61.1%(11/18) of patients, respectively. Neurological disorders(Guillian-Barre Syndrome, Moya Moya disease, encephalitis, and cranial infarction) are common(n=6(31.5%)). Malignancy is present in four(21%) patients, three suffered from diffuse large B cell lymphoma and one developed Hodgkin lymphoma. Additional clinical and laboratory results from more patients helped to define the characteristics of FCHO1 deficiency. The early application of molecular genetic analysis in CID patients is crucial. Since all transplanted patients were alive, allogeneic hematopoietic stem cell transplantation emerged as a potential curative therapy., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Immunology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
22. COVID-19 infection in children with blood cancer: A systematic review.
- Author
-
Alhumaid S, Al Noaim K, Almuslim AA, Turkistani JA, Alqurini ZS, Alshakhs AM, Al Dossary N, Alabdulqader M, Majzoub RA, Alnaim AA, Alahmari AA, Al Ghamdi MA, Alabdulmohsen W, Alsharidah ZA, Alkhamees MS, AlAithan LA, Almurayhil AA, Almurayhil YA, Aljubran HA, Alhamdan ZS, Shabib MA, Aldandan AW, Allowaim AA, Al-Rasasi AY, Albahrani AA, Al Salem BA, Bukhamseen MS, Al Ayeyd JS, Al Mutair A, Alhumaid H, Al Alawi Z, and Rabaan AA
- Abstract
Background: Blood cancer is the most common type of cancer and the leading cause of death by disease past infancy among children. Children with blood cancer are vulnerable population to viral infections such as coronavirus disease 2019 (COVID-19)., Objectives: To estimate the incidence of COVID-19 in children with blood cancer and analyse the demographic parameters, clinical characteristics and treatment outcomes in children with blood cancer with COVID-19 illness., Methods: We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline and searched ProQuest, Medline, Embase, PubMed, CINAHL, Wiley online library, Scopus and Nature for studies on the development of COVID-19 in children with blood cancer, published from December 1, 2019 to April 30, 2023, with English language restriction., Results: Of the 3077 papers that were identified, 155 articles were included in the systematic review (83 case report, 54 cohort and 18 case-series studies). Studies involving 1289 children with blood cancer with confirmed COVID-19 were analysed. Leukaemias (1141 cases) were the most frequent types of blood cancer observed in children who developed COVID-19, followed by non-Hodgkin's lymphomas (59 cases), Hodgkin's lymphomas (36 cases), Langerhans cell histiocytosis (7 cases), myelodysplastic syndrome (7 cases) and myeloid neoplasm (1 case). Among all 1289 blood cancer paediatric cases who transmitted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), some children were documented to be admitted to the intensive care unit (ICU) (n = 175, 13.6%), intubated and placed on mechanical ventilation (MV) (n = 111, 8.6%), suffered acute respiratory distress syndrome (ARDS) (n = 144, 11.2%) or died (n = 111, 8.6%). Overall, COVID-19 in children with different types of blood cancer resulted in no or low severity of disease in 78.6% of all included cases (COVID-19 severity: asymptomatic = 238, mild = 601, or moderate = 171). Treatment for COVID-19 was not necessary in a small number of children with blood cancer (n = 94, 7.3%). Fatality in children with blood cancer with COVID-19 was reported in any of the included blood cancer categories for leukaemias (n = 99/1141, 8.7%), non-Hodgkin's lymphomas (n = 7/59, 11.9%), Hodgkin's lymphomas (n = 2/36, 5.5%), myelodysplastic syndrome (n = 1/7, 14.3%) or myeloid neoplasm (n = 1/1, 100%). Fatality rate in children with blood cancer infected with SARS-CoV-2 was the highest in patients with Hispanic ethnicity (n = 44/111, 39.6%) and COVID-19-related fatality was highest in male patients (76.5% of deceased patients). Most studies reported to alter the intensity and regimen of anticancer treatment in children with blood cancer during course of SARS-CoV-2 infection, however, many studies have reported to successfully treat COVID-19 without any changes to the anticancer treatment., Conclusion: Globally, leukaemias were the most prevalent and myeloid neoplasms were the least prevalent blood cancer types in children who developed SARS-CoV-2 infection. Children with blood cancer infected with SARS-CoV-2 may experience higher rates of ICU admission and mortality in comparison with the healthy pediatric populations. Mortality in children with blood cancer and infected with SARS-CoV-2 was highest in cases belonging to male gender and Hispanic ethnicity. However, children with blood cancer tend to have milder COVID-19 symptoms and are less likely to be hospitalized and have better prognosis when compared to adults. Continuation of anticancer treatment in individual paediatric blood cancer patients with COVID-19 seems to be possible., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
23. Baseline Epitope-Specific IgE Profiles are Predictive of Sustained Unresponsiveness or High Threshold One-Year Post OIT in the POISED Trial.
- Author
-
Suprun M, Eun Lee AS, Getts R, Peck S, Sindher SB, Nadeau KC, Chinthrajah RS, Galli SJ, and Sampson H
- Abstract
Background: Results from the POISED trial suggest that discontinuation of peanut oral immunotherapy can increase the risk of regaining clinical reactivity to peanut., Objective: We sought to determine whether those who achieved sustained unresponsiveness (SU) or sustained high threshold (SHT) have different baseline sequential epitope-specific (es-) IgE profiles than those who achieved transient desensitization (TD)., Methods: Subjects in the POISED trial (NCT02103270) were randomized to peanut (n=95) or placebo (n=25) for 24 months. OIT-desensitized subjects were then assigned to no peanut (PN-0, n=51) or 300mg (PN-300, n=30) for 12 months. SU and SHT were determined by those in PN-0 and PN-300, respectively, passing 4000mg peanut oral challenge. Specific IgE and IgG4 levels to peanut, Ara h 1-3 proteins and 64 allergenic epitopes were measured. We developed machine learning glmnet models with bootstrap simulations using baseline data to predict SU/SHT., Results: Eighty (84%) subjects were desensitized to peanut. Of those, 13% (n=8) and 37% (n=13) achieved SU/SHT in PN-0 and PN-300. Decreases in epitope-and protein-specific IgE levels and increases in IgG4 levels were observed during 2 years of OIT. At baseline, patients with SU in Peanut-0 but not Peanut-300 had lower es-IgE and protein-sIgE levels compared to the TD group. A machine-learning model with 12 baseline es-IgEs and age could predict SU/SHT with an accuracy of 94%, AUC 0.97, Sensitivity 1.00, Specificity 0.91., Conclusions: Patients who achieved SU/SHT have different baseline protein-and epitope-specific IgE profiles than those with TD. These profiles may help identify patients with an increased likelihood of achieving SU/SHT., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
24. Salivary Antibody Responses to Potentially Waterborne and Environmentally Transmitted Infections Among Two Tribal Nations in the Southwest United States.
- Author
-
Wade TJ, Mistry JH, Augustine SAJ, Griffin SM, Kobylanski J, Styles J, Sams E, Hudgens E, Kowalcyk M, Cochran W, Ward H, and Egorov A
- Abstract
Purpose: Tribal Nations disproportionately lack access to safe drinking water and can be adversely affected by other water quality and environmental concerns. Such conditions could lead to an increase in the transmission of waterborne, environmental and hygiene related infections. We collected saliva samples from attendees at two Tribal Nation annual festivals and tested them for salivary immunoglobulin G (IgG) responses to selected common infections using an in-house multiplex immunoassay. Antibody responses were compared to responses from a previously conducted study in the midwestern United States., Methods: We collected and tested 531 samples from Tribal Nation sites and used data on 453 previously analyzed samples from the Midwest site. Logistic and linear regression models were used to model a binary classification of seropositivity and the intensity of the antibody response, respectively., Results: Seroprevalence of chronic infections (Helicobacter pylori and Toxoplasma gondii) were generally consistent with estimates from population-based studies. Compared to the Midwest site, one of the Tribal Nation sites had consistently higher median antibody responses to several noroviruses. The Tribal Nation sites had a lower seroprevalence of hepatitis E virus antibodies. At the Tribal Nation sites, farm residents had higher antibody responses to Cryptosporidium spp., bottled water consumption was associated with lower responses to Cryptosporidium spp., animal contact was associated with T. gondii seropositivity, and recent diarrhea was associated with higher norovirus antibody responses. Helicobacter pylori seropositivity was associated with reduced odds of reporting allergies., Conclusion: This study demonstrated the application of a multiplex salivary immunoassay in Tribal Nations to provide insights regarding selected common pathogens which are transmitted through different transmission pathways including person-to-person contacts, contaminated food, soil and drinking water., (© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.)
- Published
- 2024
- Full Text
- View/download PDF
25. scRNA-seq profiling of human granulocytes reveals expansion of developmentally flexible neutrophil precursors with mixed neutrophil and eosinophil properties in asthma.
- Author
-
Haruna NF, Politanska Y, Connelly AR, O'Connor K, Bhattacharya S, Miklaszewski GE, Pérez-Leonor XG, Rerko G, Hentenaar IT, Nguyen DC, Lamothe Molina PA, Bochner BS, Abdala-Valencia H, Gill MA, Lee FE, and Berdnikovs S
- Subjects
- Humans, Single-Cell Analysis methods, Granulocyte Precursor Cells pathology, Granulocyte Precursor Cells metabolism, Granulocytes metabolism, Granulocytes pathology, Interleukin-5 metabolism, Female, Cell Differentiation, Male, Transcriptome, Adult, RNA-Seq, Gene Expression Profiling, Single-Cell Gene Expression Analysis, Eosinophils pathology, Eosinophils metabolism, Eosinophils immunology, Asthma pathology, Asthma immunology, Asthma genetics, Neutrophils metabolism, Neutrophils pathology, Neutrophils immunology
- Abstract
Neutrophils and eosinophils share common hematopoietic precursors and usually diverge into distinct lineages with unique markers before being released from their hematopoietic site, which is the bone marrow (BM). However, previous studies identified an immature Ly6g(+) Il-5Rα(+) neutrophil population in mouse BM, expressing both neutrophil and eosinophil markers suggesting hematopoietic flexibility. Moreover, others have reported neutrophil populations expressing eosinophil-specific cell surface markers in tissues and altered disease states, confusing the field regarding eosinophil origins, function, and classification. Despite these reports, it is still unclear whether hematopoietic flexibility exists in human granulocytes. To answer this, we utilized single-cell RNA sequencing and cellular indexing of transcriptomes and epitopes by sequencing to profile human BM and circulating neutrophils and eosinophils at different stages of differentiation and determine whether neutrophil plasticity plays role in asthmatic inflammation. We show that immature metamyelocyte neutrophils in humans expand during severe asthmatic inflammation and express both neutrophil and eosinophil markers. We also show an increase in trilobed eosinophils with mixed neutrophil and eosinophil markers in allergic asthma and that interleukin-5 promotes differentiation of immature blood neutrophils into trilobed eosinophilic phenotypes, suggesting a mechanism of emergency granulopoiesis to promote myeloid inflammatory or remodeling response in patients with chronic asthma. By providing insights into unexpectedly flexible granulocyte biology and demonstrating emergency hematopoiesis in asthma, our results highlight the importance of granulocyte plasticity in eosinophil development and allergic diseases., Competing Interests: Conflict of interest statement. None declared., (© The Author(s) 2024. Published by Oxford University Press on behalf of Society for Leukocyte Biology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
26. An International Delphi Consensus on the Management of Pollen-Food-Allergy Syndrome: A Work Group Report of the AAAAI Adverse Reactions to Foods Committee.
- Author
-
Al-Shaikhly T, Cox A, Nowak-Wegrzyn A, Cianferoni A, Katelaris C, Ebo DG, Konstantinou GN, Brucker H, Yang HJ, Protudjer JLP, Boechat JL, Yu JE, Wang J, Hsu Blatman KS, Blazowski L, Anand MP, Ramesh M, Torres MJ, Holbreich M, Goodman R, Wasserman RL, Hopp R, Sato S, and Skypala I
- Abstract
Background: Pollen-food-allergy syndrome (PFAS) is common among patients with allergic rhinitis. Treatment recommendations for patients with PFAS remain variable., Objective: To develop consensus recommendation statements for managing patients with PFAS., Methods: An international panel of allergists, researchers, and nutritionists with an interest in PFAS from 25 different institutions across 11 countries convened and a list of statements was written by 3 authors. The RAND/University of California Los Angeles methodology was adopted to establish consensus on the statements., Results: After 2 Delphi rounds, a consensus was reached on 14 statements. The panel agreed that patients with PFAS would benefit from counseling on the nature and basis of PFAS and the rare chance of more severe systemic reactions and their recognition. The panel agreed on avoiding the raw food responsible for the index reaction, but not potentially cross-reactive fruits/vegetables based on the responsible food of the index reaction. Epinephrine autoinjectors should be recommended for patients with PFAS who experienced severe symptoms (beyond the oropharynx) or for patients considered at risk for severe reactions. The panel agreed that the benefit of allergen immunotherapy remains unclear and that PFAS should not be considered the primary indication for such intervention., Conclusions: We developed consensus statements regarding counselling patients about the nature and severity of PFAS, potential risk factors, dietary avoidance, epinephrine autoinjector prescription, and allergen immunotherapy consideration for patients with PFAS., (Copyright © 2024 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
27. AAAAI Position Statement on Changing Electronic Health Record Allergy Documentation to "Alerts" to Lead to Easily Understood, Actionable Labels.
- Author
-
White AA, Ramsey A, Guyer A, Israelsen RB, Khan F, Kaplan B, Kumar S, Blumenthal KG, Risma K, Kakumanu S, and Macy E
- Abstract
The term "allergy" is inaccurate for the vast majority of the contents in the current allergy fields of electronic health records (EHRs). While EHRs have transformed access to health information and streamlined the delivery of care, their ability to reliably indicate medications, vaccines, or foods that mandate avoidance versus preferences or mild intolerances, is suboptimal. The current systems are reactive instead of being proactive and frequently fail to communicate the appropriate course of action. This Position Statement of the American Academy of Allergy, Asthma and Immunology (AAAAI) advocates for a change in terminology. The section of the EHR currently labeled "allergies" should be renamed "alerts." The term "alert" accurately captures the purpose of this section without incorrectly assigning an allergic mechanism, and prioritizes easily understood and actionable labels. This change has the potential to simultaneously improve patient safety and care. This shift will be the first step in the transformation of the alerts section of the EHR. This document provides a framework for categorizing what should be included in this section. Enacting these changes will require EHR and clinical decision support vendors, healthcare and data standard regulators, allergists, and the larger health care community to work together to bring about these important advances., (Copyright © 2024 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
28. Distinct Escherichia coli transcriptional profiles in the guts of recurrent UTI sufferers revealed by pangenome hybrid selection.
- Author
-
Young MG, Straub TJ, Worby CJ, Metsky HC, Gnirke A, Bronson RA, van Dijk LR, Desjardins CA, Matranga C, Qu J, Villicana JB, Azimzadeh P, Kau A, Dodson KW, Schreiber HL 4th, Manson AL, Hultgren SJ, and Earl AM
- Subjects
- Humans, Female, Recurrence, Feces microbiology, Gastrointestinal Microbiome genetics, Adult, Gastrointestinal Tract microbiology, Urinary Tract Infections microbiology, Urinary Tract Infections genetics, Escherichia coli Infections microbiology, Escherichia coli Infections genetics, Transcriptome genetics, Escherichia coli genetics, Uropathogenic Escherichia coli genetics, Genome, Bacterial genetics
- Abstract
Low-abundance members of microbial communities are difficult to study in their native habitats, including Escherichia coli, a minor but common inhabitant of the gastrointestinal tract, and key opportunistic pathogen of the urinary tract. While multi-omic analyses have detailed interactions between uropathogenic Escherichia coli (UPEC) and the bladder mediating urinary tract infection (UTI), little is known about UPEC in its pre-infection reservoir, the gastrointestinal tract, partly due to its low relative abundance (<1%). To sensitively explore the genomes and transcriptomes of diverse gut E. coli, we develop E. coli PanSelect, which uses probes designed to specifically capture E. coli's broad pangenome. We demonstrate its ability to enrich diverse E. coli by orders of magnitude, in a mock community and in human stool from a study investigating recurrent UTI (rUTI). Comparisons of transcriptomes between gut E. coli of women with and without history of rUTI suggest rUTI gut E. coli are responding to increased oxygen and nitrate, suggestive of mucosal inflammation, which may have implications for recurrent disease. E. coli PanSelect is well suited for investigations of in vivo E. coli biology in other low-abundance environments, and the framework described here has broad applicability to other diverse, low-abundance organisms., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
29. Corrigendum to <'A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology'> <[Annals of Allergy, Asthma & Immunology 133 (2024) 286-94]>.
- Author
-
Lieberman JA, Chu DK, Ahmed T, Dribin TE, Abrams EM, Anagnostou A, Blumenthal KG, Boguniewicz M, Chase NM, Golden DBK, Hartog NL, Heimall JR, Ho T, Lawrence MG, Khan DA, Minniear TD, Mustafa SS, Oppenheimer JJ, Phillips EJ, Ramsey A, Rider NL, Schneider L, Shaker MS, Spergel JM, Stone CA Jr, Stukus DR, Wang J, and Greenhawt MJ
- Published
- 2024
- Full Text
- View/download PDF
30. GA 2 LEN ANACARE consensus statement: Potential of omalizumab in food allergy management.
- Author
-
Zuberbier T, Muraro A, Nurmatov U, Arasi S, Stevanovic K, Anagnostou A, Bonaguro R, Chinthrajah S, Lack G, Fiocchi A, Le TM, Turner P, Lozano MA, Angier E, Barni S, Bégin P, Ballmer-Weber B, Cardona V, Bindslev-Jensen C, Cianferoni A, de Jong N, de Silva D, Deschildre A, Galvin AD, Ebisawa M, Fleischer DM, Gerdts J, Giovannini M, Gradman J, Halken S, Arshad SH, Khaleva E, Lau S, Loh R, Mäkelä MJ, Marchisotto MJ, Morandini L, Mortz CG, Nilsson C, Nowak-Wegrzyn A, Podestà M, Poulsen LK, Roberts G, Rodríguez Del Río P, Sampson HA, Sánchez A, Schnadt S, Smith PK, Szajewska H, Mitrevska NT, Toniolo A, Venter C, Warner A, Wong GWK, Wood R, and Worm M
- Abstract
Immunoglobulin E (IgE)-mediated food allergies are the most common type of food allergy, often causing rapid symptoms after exposure to allergens posing a serious health risk and a high impact on patient's and caregiver's quality of life. Omalizumab, a humanized anti-IgE monoclonal antibody, reduces allergic reactions by binding to circulating IgE. Omalizumab has been successfully used in allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, and was recently approved for treating IgE-mediated food allergies by the US Food and Drug Administration (FDA). This GA
2 LEN ANACARE Consensus Statement presents our position on the use of omalizumab for treating IgE-mediated food allergies, based on a systematic review and meta-analysis, experience with use for other conditions, and expert consensus achieved via an eDelphi process. Following publication of the recent OUtMATCH study (stage 1) results and subsequent FDA approval, we propose that there is now sufficient evidence to recommend omalizumab as the only drug currently available that can mechanistically reduce IgE-mediated food allergic reactions. We acknowledge that the evidence does not reach the highest level of evidence which would be needed for a guideline recommendation., (© 2024 The Author(s). Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.)- Published
- 2024
- Full Text
- View/download PDF
31. Empiric elimination diets for eosinophilic esophagitis: barriers, facilitators, and impact on quality of life.
- Author
-
Mehta P, Pan Z, Furuta GT, and Kliewer K
- Published
- 2024
- Full Text
- View/download PDF
32. The future of allergy and immunology research: 2024 American College of Allergy, Asthma and Immunology Annals Fellow-in-Training award winners.
- Author
-
Grayson MH
- Published
- 2024
- Full Text
- View/download PDF
33. The protective power of cats.
- Author
-
Nguyen V and Khan F
- Abstract
Competing Interests: Disclosures Dr Khan reports having shares in Doximity. The remaining author has no conflicts of interest to report.
- Published
- 2024
- Full Text
- View/download PDF
34. How I treat eosinophilic esophagitis.
- Author
-
Spergel JM
- Abstract
Competing Interests: Disclosures Dr Spergel has no conflicts of interest to report.
- Published
- 2024
- Full Text
- View/download PDF
35. Asthma Biologics: Lung Function, Steroid-Dependence, and Exacerbations.
- Author
-
Salciccioli JD and Israel E
- Subjects
- Humans, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal pharmacology, Disease Progression, Respiratory Function Tests, Lung immunology, Lung drug effects, Lung metabolism, Interleukin-5 antagonists & inhibitors, Interleukin-5 metabolism, Interleukin-5 immunology, Steroids therapeutic use, Asthma drug therapy, Asthma immunology, Biological Products therapeutic use, Biological Products pharmacology, Anti-Asthmatic Agents therapeutic use, Anti-Asthmatic Agents pharmacology
- Abstract
The development of multiple targeted biologic therapies over the past two decades has revolutionized the management of asthma. Currently, there are 6 monoclonal antibodies that target specific inflammatory mediators involved in the pathophysiology of asthma, and together, they provide the opportunity for personalized treatment options beyond bronchodilators and inhaled or systemic glucocorticoids in severe and difficult-to-control cases of asthma. These agents are the anti-IgE antibody omalizumab, the anti-IL-5 antibodies mepolizumab and reslizumab, the IL-5 receptor alpha antagonist benralizumab, the IL-4 receptor alpha antagonist dupilumab, and the anti-thymic stromal lymphopoietin antibody tezepelumab., Competing Interests: Disclosures J.D. Salciccioli has no financial disclosures to declare. E. Israel reports the following: grants and contracts: AstraZeneca, Avillion, Gossamer Bio, National Institutes of Health (NIH), Patient-Centered Outcomes Research Institute (PCORI); royalties or licenses: UpToDate; consulting fees: Amgen, Arrowhead Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Merck, Regeneron, Sanofi, TEVA, Guidepoint, Windrose Consulting Group, Reach Market Research, Apogee Therapeutics, Yuhan, Leerink Partners; honoraria: Clearview Health Partners; support for attending meeting/travel: AstraZeneca; participation on a data safety monitoring board: Novartis; receipt of equipment, materials, drugs, medical writing, or other services: Genentech, Sun Pharma, Laurel Pharmaceuticals, Om Pharma, Nestle, CLS Behring, Sanofi-Regeneron., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
36. Biologics in Asthma: Potential to Achieve Clinical Remission.
- Author
-
Rivera O 2nd, Katial R, and Hoyte FCL
- Subjects
- Humans, Treatment Outcome, Practice Guidelines as Topic, Asthma drug therapy, Asthma diagnosis, Asthma therapy, Biological Products therapeutic use, Remission Induction, Anti-Asthmatic Agents therapeutic use
- Abstract
Establishing a universal definition for asthma remission has the potential to improve asthma outcomes and advance research. However, there is still no consensus definition despite broad multidisciplinary efforts to achieve this goal. This study explores the evolving concept of asthma remission, emphasizing the potential of biologics to achieve this state. We will discuss various proposed definitions of asthma remission, international guidelines, and studies evaluating the effectiveness of biologics at achieving clinical remission. We highlight the need for a consensus definition of asthma remission to standardize treatment goals and improve patient outcomes., Competing Interests: Disclosure R.K. Katial: AstraZeneca: Advisory, speaking; Sanofi/Regeneron: Advisory, speaking; GSK: Advisory. F.C.L. Hoyte: AstraZeneca: Advisory, speaking; GSK: Advisory; Genentech: Advisory; Teva: Advisory; Sanofi: Advisory., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
37. Advancements in Biologic Therapies for Eosinophilic Gastrointestinal Diseases: A Comprehensive Review.
- Author
-
Melhem RA and Hassoun Y
- Subjects
- Humans, Enteritis drug therapy, Enteritis therapy, Enteritis diagnosis, Enteritis immunology, Biological Products therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Eosinophilic Esophagitis drug therapy, Eosinophilic Esophagitis therapy, Eosinophilic Esophagitis immunology, Eosinophilic Esophagitis diagnosis, Antibodies, Monoclonal therapeutic use, Eosinophils immunology, Eosinophils metabolism, Animals, Eosinophilia drug therapy, Eosinophilia immunology, Eosinophilia diagnosis, Biological Therapy methods, Biological Therapy trends, Gastritis diagnosis, Gastritis drug therapy, Gastritis immunology, Gastritis therapy
- Abstract
Eosinophilic gastrointestinal diseases (EGIDs) encompass a group of disorders characterized by an abnormal accumulation of eosinophils in various parts of the gastrointestinal tract. EGIDs present with a wide range of symptoms such as abdominal pain, vomiting, diarrhea, difficulty swallowing, and food impaction. Monoclonal antibodies, targeting inflammatory cytokines or eosinophils, are the next emerging therapy for EGIDs. The only Food and Drug Administration-approved monoclonal antibody is dupilumab, and it has been approved for the treatment of eosinophilic esophagitis (EoE). In this article, the authors will discuss biologics that have been used in the treatment of eosinophilic gastrointestinal diseases., Competing Interests: Disclosures The authors have nothing to disclose., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
38. Biologics in Food Allergies: Emerging Therapies.
- Author
-
Beaudoin M, Citron C, and Brar KK
- Subjects
- Humans, Desensitization, Immunologic methods, Allergens immunology, Immunoglobulin E immunology, Immunoglobulin E metabolism, Food Hypersensitivity therapy, Food Hypersensitivity immunology, Biological Products therapeutic use, Biological Products adverse effects, Anti-Allergic Agents therapeutic use, Omalizumab therapeutic use
- Abstract
Immunoglobuin E (IgE)-mediated food allergies greatly impact patients and their families, causing financial and emotional stress, and placing them at risk for lifethreatening reactions. Until recently, food allergies have been treated with allergen avoidance and emergency treatment of allergic reactions. Omalizumab was recently approved in adults and children greater than one year who are allergic to one or more foods for the prevention of serious allergic reactions in the setting of accidental exposure. Omalizumab also shows promise when combined with oral immunotherapy for possible allergen ingestion. Other classes of biologics and small molecule inhibitors have also demonstrated potential for use in preventing and treating food allergy., Competing Interests: Disclosure K.K. Brar has served as an advisor and received research support from Incyte Pharmaceuticals. She is an investigator for Sanofi, and Siolta Therapeutics., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
39. Advances in omics data for eosinophilic esophagitis: moving towards multi-omics analyses.
- Author
-
Matsuyama K, Yamada S, Sato H, Zhan J, and Shoda T
- Subjects
- Humans, Machine Learning, Transcriptome, Gene Expression Profiling methods, Epigenesis, Genetic, Biomarkers metabolism, Quality of Life, Multiomics, Eosinophilic Esophagitis genetics, Genomics methods, Proteomics methods
- Abstract
Eosinophilic esophagitis (EoE) is a chronic, allergic inflammatory disease of the esophagus characterized by eosinophil accumulation and has a growing global prevalence. EoE significantly impairs quality of life and poses a substantial burden on healthcare resources. Currently, only two FDA-approved medications exist for EoE, highlighting the need for broader research into its management and prevention. Recent advancements in omics technologies, such as genomics, epigenetics, transcriptomics, proteomics, and others, offer new insights into the genetic and immunologic mechanisms underlying EoE. Genomic studies have identified genetic loci and mutations associated with EoE, revealing predispositions that vary by ancestry and indicating EoE's complex genetic basis. Epigenetic studies have uncovered changes in DNA methylation and chromatin structure that affect gene expression, influencing EoE pathology. Transcriptomic analyses have revealed a distinct gene expression profile in EoE, dominated by genes involved in activated type 2 immunity and epithelial barrier function. Proteomic approaches have furthered the understanding of EoE mechanisms, identifying potential new biomarkers and therapeutic targets. However, challenges in integrating diverse omics data persist, largely due to their complexity and the need for advanced computational methods. Machine learning is emerging as a valuable tool for analyzing extensive and intricate datasets, potentially revealing new aspects of EoE pathogenesis. The integration of multi-omics data through sophisticated computational approaches promises significant advancements in our understanding of EoE, improving diagnostics, and enhancing treatment effectiveness. This review synthesizes current omics research and explores future directions for comprehensively understanding the disease mechanisms in EoE., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
40. High symptom burden in female X-linked chronic granulomatous disease carriers.
- Author
-
Miranda MA, Tsalatsanis A, Trotter JR, Arnold DE, Squire JD, Kidd S, Parikh S, Marsh RA, Griffith LM, Mallhi K, Chellapandian D, Lim SS, Grunebaum E, Sullivan KE, Newburger PE, Dinauer MC, Cowan MJ, Dvorak CC, Haddad E, Kohn DB, Notarangelo LD, Pai SY, Puck JM, Pulsipher MA, Torgerson TR, Malech HL, Kang EM, Morton FB, and Leiding JW
- Published
- 2024
- Full Text
- View/download PDF
41. Antepartum vs postpartum amoxicillin oral challenge in pregnant patients with a reported penicillin allergy: A two-center prospective cohort study.
- Author
-
Wong JMH, Liu X, Mak R, Erdle SC, Barber C, van Schalkwyk J, Watt M, Ande SR, Ochulor D, Elwood C, and Poliquin V
- Subjects
- Humans, Female, Pregnancy, Prospective Studies, Adult, Administration, Oral, Skin Tests, Postpartum Period, Prenatal Care methods, Cohort Studies, Drug Hypersensitivity, Amoxicillin adverse effects, Amoxicillin administration & dosage, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents administration & dosage, Penicillins adverse effects
- Abstract
Introduction: While 10% of pregnant individuals report a penicillin allergy, there is no established best practice for penicillin allergy delabeling in pregnancy. To better understand options for penicillin delabeling, we aimed to evaluate two penicillin allergy delabeling protocols in pregnancy regarding efficacy, adverse events, and patient satisfaction., Material and Methods: From July 2019 to December 2022, we completed a two-center prospective cohort study, where each site recruited pregnant patients over 24 weeks gestational age with a reported penicillin allergy. One center offered antepartum amoxicillin oral challenges, either directly or after negative skin testing (i.e., antepartum oral challenge site). Our other centers completed a two-step approach with antepartum penicillin skin testing only and deferred oral challenges to the postpartum period (i.e., postpartum oral challenge site). Our primary outcome was the rate of penicillin allergy delabeling, defined as tolerating an antibiotic challenge with penicillin or amoxicillin. Univariate analyses were completed using chi-squared, Fisher's exact, and Wilcoxon rank tests., Results: During the study period, 276 pregnant patients were assessed, with 207 in the antepartum oral challenge site and 69 in the postpartum oral challenge site. Among the 204 patients who completed antepartum oral challenges, 201 (98%) passed without reactions. Deferring oral challenges to the postpartum period led to a loss of follow-up for 37/53 (70%) of eligible individuals. Overall, 97% (201/207) of patients at the antepartum oral challenge site were delabeled from their penicillin allergy-compared to 38% (26/69) of patients referred to the postpartum oral challenge site (p < 0.0001). Three antepartum oral challenge reactions were noted, including two mild cutaneous reactions and a case of transient abdominal discomfort., Conclusions: Antepartum amoxicillin oral challenge is a more effective method to delabel pregnant patients from their penicillin allergy. Deferral of oral challenges to the postpartum period introduces a significant barrier for penicillin allergy delabeling., (© 2024 The Author(s). Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).)
- Published
- 2024
- Full Text
- View/download PDF
42. IL-22Ra2 Levels Remain Elevated in People with Cystic Fibrosis despite Modulator Therapy.
- Author
-
Bojanowski CM, Lee SE, Trevejo-Nunez G, Bomberger JM, Schleimer RP, Saavedra MT, and Kolls JK
- Published
- 2024
- Full Text
- View/download PDF
43. Disease heterogeneity and molecular classification of inflammatory palmoplantar diseases.
- Author
-
van Straalen KR, Kirma J, Yee CM, Bugada LF, Rizvi SM, Wen F, Wasikowski R, Fox J, Do TH, Schuler CF 4th, Xing E, MacLeod AS, Harms PW, Berthier CC, Kahlenberg JM, Leung MWL, Tsoi LC, and Gudjonsson JE
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Transcriptome, Cytokines immunology, Cytokines genetics, Skin pathology, Skin immunology, Aged, Eczema classification, Eczema immunology, Eczema genetics, Psoriasis immunology, Psoriasis genetics, Psoriasis classification
- Abstract
Background: Palmoplantar pustulosis (PPP) is an inflammatory disease characterized by relapsing eruptions of neutrophil-filled, sterile pustules on the palms and soles that can be clinically difficult to differentiate from non-pustular palmoplantar psoriasis (palmPP) and dyshidrotic palmoplantar eczema (DPE)., Objective: We sought to identify overlapping and unique PPP, palmPP, and DPE drivers to provide molecular insight into their pathogenesis., Methods: We performed bulk RNA sequencing of lesional PPP (n = 33), palmPP (n = 5), and DPE (n = 28) samples, as well as 5 healthy nonacral and 10 healthy acral skin samples., Results: Acral skin showed a unique immune environment, likely contributing to a unique niche for palmoplantar inflammatory diseases. Compared to healthy acral skin, PPP, palmPP, and DPE displayed a broad overlapping transcriptomic signature characterized by shared upregulation of proinflammatory cytokines (TNF, IL-36), chemokines, and T-cell-associated genes, along with unique disease features of each disease state, including enriched neutrophil processes in PPP and to a lesser extent in palmPP, and lipid antigen processing in DPE. Strikingly, unsupervised clustering and trajectory analyses demonstrated divergent inflammatory profiles within the 3 disease states. These identified putative key upstream immunologic switches, including eicosanoids, interferon responses, and neutrophil degranulation, contributing to disease heterogeneity., Conclusion: A molecular overlap exists between different inflammatory palmoplantar diseases that supersedes clinical and histologic assessment. This highlights the heterogeneity within each condition, suggesting limitations of current disease classification and the need to move toward a molecular classification of inflammatory acral diseases., Competing Interests: Disclosure statement Supported by an unrestricted research grant from Janssen. Additional support was provided by P30-AR075043 (J.E.G., L.C.T.), the Alfred A. Taubman Medical Research Institute (J.E.G., J.M.K.), and the George M. O’Brien Michigan Kidney Translational Research Core Center P30DK081943 (C.C.B.). C.F.S. is supported by K23–NIH/NIAID K23AI162661. F.W. is supported by the Taubman Institute Innovation Projects program. Disclosure of potential conflict of interest: K. R. van Straalen has received honoraria from Novartis, Boehringer-Ingelheim, and UCB. A. S. MacLeod is currently employed by Janssen Pharmaceuticals. J. M. Kahlenberg has received grant support from Q32 Bio, Celgene/Bristol Myers Squibb (BMS), Ventus Therapeutics, ROME Therapeutics, and Janssen; and has served on advisory boards for AstraZeneca, Eli Lilly, GlaxoSmithKline, BMS, Avion Pharmaceuticals, Provention Bio, Aurinia Pharmaceuticals, Ventus Therapeutics, Gilead, and EMD Serano. M. W. L. Leung is currently employed by Janssen R&D LLC, San Diego, Calif. J. E. Gudjonsson has received grant support from Celgene/BMS, Janssen, Eli Lilly, and Almirall and has served on advisory boards for AstraZeneca, Sanofi, Eli Lilly, Boehringer Ingelheim, Novartis, Janssen, Almirall, and BMS. The rest of the authors declare that they have no relevant conflicts of interest., (Copyright © 2024 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
44. Current use and interest in complementary and alternative medicine in an academic allergy clinic.
- Author
-
Cronin KJ, Barratt J, and Tripple JW
- Abstract
Competing Interests: Disclosures The authors have no conflicts of interest to report.
- Published
- 2024
- Full Text
- View/download PDF
45. Preclinical efficacy of peanut-specific IgG4 antibody therapeutic IGNX001.
- Author
-
Croote D, Wong JJW, Creeks P, Aruva V, Landers JJ, Kwok M, Jama Z, Hamilton RG, Santos AF, O'Konek JJ, Ferrini R, Thomas GR, and Lowman HB
- Subjects
- Humans, Animals, Mice, Antigens, Plant immunology, Antibodies, Monoclonal immunology, Antibodies, Monoclonal therapeutic use, Female, 2S Albumins, Plant immunology, Allergens immunology, Mast Cells immunology, Basophils immunology, Disease Models, Animal, Peanut Hypersensitivity immunology, Peanut Hypersensitivity therapy, Immunoglobulin G immunology, Immunoglobulin E immunology, Arachis immunology
- Abstract
Background: Existing therapeutic strategies are challenged by long times to achieve effect and often require frequent administration. Peanut-allergic individuals would benefit from a therapeutic that provides rapid protection against accidental exposure within days of administration while carrying little risk of adverse reactions., Objective: Guided by the repertoire of human IgE mAbs from allergic individuals, we sought to develop a treatment approach leveraging the known protective effects of allergen-specific IgG4 antibodies., Methods: We applied our single-cell RNA-sequencing SEQ SIFTER platform (IgGenix, Inc, South San Francisco, Calif) to whole blood samples from peanut-allergic individuals to discover IgE mAbs. These were then class-switched by replacing the IgE constant region with IgG4 while retaining the allergen-specific variable regions. In vitro mast cell activation tests, basophil activation tests, ELISAs, and an in vivo peanut allergy mouse model were used to evaluate the specificity, affinity, and activity of these recombinant IgG4 mAbs., Results: We determined that human peanut-specific IgE mAbs predominantly target immunodominant epitopes on Ara h 2 and Ara h 6 and that recombinant IgG4 mAbs effectively block these epitopes. IGNX001, a mixture of 2 such high-affinity IgG4 mAbs, provided robust protection against peanut-mediated mast cell activation in vitro as well as against anaphylaxis upon intragastric peanut challenge in a peanut allergy mouse model., Conclusions: We developed a peanut-specific IgG4 antibody therapeutic with convincing preclinical efficacy starting from a large repertoire of human IgE mAbs from demographically and geographically diverse individuals. These results warrant further clinical investigation of IGNX001 and underscore the opportunity for the application of this therapeutic development strategy in other food and environmental allergies., Competing Interests: Disclosure statement The study was supported by IgGenix. A.F.S. acknowledges grants from the Medical Research Council (grant nos. MR/M008517/1, MC/PC/18052, and MR/T032081/1), Food Allergy Research and Education, the Immune Tolerance Network/National Institute of Allergy and Infectious Diseases, Asthma UK (grant no. AUK-BC-2015-01), Biotechnology and Biological Sciences Research Council (BBSRC), Rosetrees Trust, and the National Institute for Health and Care Research (NIHR) through the Biomedical Research Centre award to Guy’s and St Thomas’ National Health Service Foundation Trust during the conduct of the study. Disclosure of potential conflict of interest: D. Croote, J. J. W. Wong, P. Creeks, V. Aruva, R. Ferrini, G. R. Thomas, and H. B. Lowman are employees of, and/or stakeholders in, IgGenix. Patent applications assigned to IgGenix have been filed covering aspects of this work. R. G. Hamilton is a consultant for IgGenix. A. F. Santos received personal fees from Thermo Fisher Scientific, Novartis, Allergy Therapeutics, Nestle, and IgGenix; and received research support from IgGenix and Thermo Fisher Scientific through collaboration agreements with King’s College London. The rest of the authors declare that they have no relevant conflicts of interest., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
46. Age differences in inducible laryngeal obstruction in adult populations.
- Author
-
Luedders J, May S, Lyden E, Rorie A, Graaff JV, Zamora-Sifuentes J, Walenz R, and Poole JA
- Subjects
- Humans, Middle Aged, Male, Adult, Female, Aged, Age Factors, Young Adult, Surveys and Questionnaires, Laryngeal Diseases physiopathology, Adolescent, Airway Obstruction diagnosis
- Abstract
Background: Whereas differences in inducible laryngeal obstruction (ILO) presentation on the basis of age have been observed within pediatric populations, age-based differences in adult populations are lacking., Objective: To describe differences in ILO on the basis of age in adults., Methods: Patients aged older than 16 years with confirmed ILO (vocal cord adduction > 50% during inspiration) by means of provocation-challenge rhinolaryngoscopy by their treating allergist were included. An investigator-designed questionnaire was administered using Research Electronic Data Capture with corresponding medical data collection. χ
2 tests, Student's t tests, analysis of variance, Cochran-Armitage test for trend, and Fisher's exact test were used., Results: The median age of the 67 patients was 50 years. P values less than .05 were considered significant. Those aged younger than 50 years (n = 31; mean age 35.6 years) reported more symptoms vs age 50 years and older (n = 36; mean age 61.8 years), including shortness of breath at rest and exertion (84% vs 39%, 94% vs 72%), throat tightness (81% vs 50%), chest tightness (81% vs 47%), and difficulty getting air in (81% vs 56%). Those aged younger than 50 years had an increased history of anxiety (68% vs 33%), asthma (55% vs 31%), positive methacholine challenge (52% vs 22%), increasing triggers with time (87% vs 43%), higher Pittsburgh Vocal Cord Dysfunction Index Scores (6.9 vs 5.5), and inspiratory curve flattening (48% vs 24%). Additional age-based subdivisions confirmed significant trends with the lowest reported ILO characteristics and symptoms in those aged 65 years and older., Conclusion: A high index of suspicion for ILO should be maintained in older adults since they may report less typical ILO symptoms and anxiety associations that prompt ILO evaluation., Competing Interests: Disclosures Dr Poole has received research regents (no monies) from AstraZeneca. Dr Poole, Dr Van De Graaff, Dr May, Dr Rorie, and Ms Walenz are site recruiters for clinical studies for asthma, sinus disease, and urticaria for GlaxoSmithKline, AstraZeneca, Regeneron Pharmaceuticals, and CellDex Therapeutics. The remaining authors have no conflicts of interest to report., (Published by Elsevier Inc.)- Published
- 2024
- Full Text
- View/download PDF
47. Differences in familiarity with oral immunotherapy among caregivers of White and Black children with food allergy.
- Author
-
Bannon M, Thivalapill N, Fithian E, Jiang J, Herbert L, Fox S, Warren C, Sharma H, Mahdavinia M, Gupta R, Bilaver L, and Assa'Ad A
- Subjects
- Adult, Child, Child, Preschool, Female, Humans, Male, Administration, Oral, Health Knowledge, Attitudes, Practice ethnology, Hispanic or Latino, Prospective Studies, Surveys and Questionnaires, Black or African American, Caregivers psychology, Desensitization, Immunologic methods, Food Hypersensitivity therapy, Food Hypersensitivity ethnology, White
- Abstract
Background: Potential racial and ethnic disparities related to oral immunotherapy (OIT) have not been fully described among children with food allergy (FA)., Objective: To characterize the differences in attitudes toward, familiarity with, and utilization of OIT among non-Hispanic White (NHW), non-Hispanic Black (NHB), and Hispanic or Latino (H/L) caregivers of children with FA., Methods: Surveys were administered to the caregivers of children enrolled in Food Allergy Outcomes Related to White and African American Racial Differences, a prospective, multisite cohort of children with FA. The distribution of responses by caregiver-reported race and ethnicity was described using an analysis of variance for continuous outcomes and χ
2 tests for categorical outcomes. A logistic regression model was used to determine associations between familiarity with OIT as a treatment option and various other covariates., Results: The NHB and H/L respondents were more frequently not familiar with OIT compared with NHW responders (54.3% and 62.5% vs 9.2%, P < .001). This finding remained true, even after adjusting for household income (odds ratio: 0.1, 95% CI: 0.1-0.4 for NHB participants and odds ratio: 0.1, 95% CI: 0.0-0.3 for H/L participants). NHB and H/L participants more frequently reported that they had never heard of OIT before the survey compared with NHW participants (76.7% and 50.0% vs 26.7%, P < .001). None of the NHB and H/L respondents initiated OIT compared with 14.8% of NHW participants (P < .001)., Conclusion: In the Food Allergy Outcomes Related to White and African American Racial Differences cohort, familiarity with OIT was lower among caregivers of minoritized racial and ethnic groups, even after adjusting for household income., Competing Interests: Disclosures The authors have no conflicts of interest to report., (Copyright © 2024 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
48. Biomarkers in asthma, potential for therapeutic intervention.
- Author
-
Pasha MA, Hopp RJ, Habib N, and Tang DD
- Subjects
- Humans, Cytokines, Inflammation immunology, Inflammation diagnosis, Sputum, Phenotype, Anti-Asthmatic Agents therapeutic use, Asthma drug therapy, Asthma diagnosis, Asthma immunology, Biomarkers analysis, Biomarkers metabolism
- Abstract
Asthma is a heterogeneous disease characterized by multiple phenotypes with varying risk factors and therapeutic responses. This Commentary describes research on biomarkers for T2-"high" and T2-"low" inflammation, a hallmark of the disease. Patients with asthma who exhibit an increase in airway T2 inflammation are classified as having T2-high asthma. In this endotype, Type 2 cytokines interleukins (IL)-4, IL-5, and IL-13, plus other inflammatory mediators, lead to increased eosinophilic inflammation and elevated fractional exhaled nitric oxide (FeNO). In contrast, T2-low asthma has no clear definition. Biomarkers are considered valuable tools as they can help identify various phenotypes and endotypes, as well as treatment response to standard treatment or potential therapeutic targets, particularly for biologics. As our knowledge of phenotypes and endotypes expands, biologics are increasingly integrated into treatment strategies for severe asthma. These treatments block specific inflammatory pathways or single mediators. While single or composite biomarkers may help to identify subsets of patients who might benefit from these treatments, only a few inflammatory biomarkers have been validated for clinical application. One example is sputum eosinophilia, a particularly useful biomarker, as it may suggest corticosteroid responsiveness or reflect non-compliance to inhaled corticosteroids. As knowledge develops, a meaningful goal would be to provide individualized care to patients with asthma.
- Published
- 2024
- Full Text
- View/download PDF
49. Long-term durability between parent and child patient-reported outcomes in eosinophilic esophagitis.
- Author
-
Martin LJ, Zhang X, Chehade M, Davis CM, Dellon ES, Falk GW, Gupta SK, Hirano I, Hiremath GS, Katzka DA, Khoury P, Leung J, Menard-Katcher P, Gonsalves N, Pesek RD, Spergel JM, Wechsler JB, Kliewer K, Arva NC, Collins MH, Pletneva M, Yang GY, Furuta GT, Rothenberg ME, and Aceves SS
- Subjects
- Humans, Male, Female, Child, Child, Preschool, Surveys and Questionnaires, Adolescent, Longitudinal Studies, Self Report, Eosinophilic Esophagitis therapy, Patient Reported Outcome Measures, Parents psychology, Quality of Life
- Abstract
Background: Because young children cannot self-report symptoms, there is a need for parent surrogate reports. Although early work suggested parent-child alignment for eosinophil esophagitis (EoE) patient-reported outcomes (PROs), the longitudinal alignment is unclear., Objective: We sought to assess the agreement and longitudinal stability of PROs between children with EoE and their parents., Methods: A total of 292 parent-child respondents completed 723 questionnaires over 5 years in an observational trial in the Consortium of Eosinophilic Gastrointestinal Disease Researchers. The change in and agreement between parent and child Pediatric Eosinophilic Esophagitis Symptom Score version 2 (PEESSv2.0) and Pediatric Quality of Life Eosinophilic Esophagitis Module (PedsQL-EoE) PROs over time were assessed using Pearson correlation and Bland-Altman analyses. Clinical factors influencing PROs and their agreement were evaluated using linear mixed models., Results: The cohort had a median disease duration equaling 3.7 years and was predominantly male (73.6%) and White (85.3%). Child and parent PEESSv2.0 response groups were identified and were stable over time. There was strong correlation between child and parent reports (PEESSv2.0, 0.83;PedsQL-EoE, 0.74), with minimal pairwise differences for symptoms. Longitudinally, parent-reported PedsQL-EoE scores were stable (P ≥ .32), whereas child-reported PedsQL-EoE scores improved (P = .026). A larger difference in parent and child PedsQL-EoE reports was associated with younger age (P < .001), and differences were driven by psychosocial PRO domains., Conclusions: There is strong longitudinal alignment between child and parent reports using EoE PROs. These data provide evidence that parent report is a stable proxy for objective EoE symptoms in their children., Competing Interests: Disclosure statement CEGIR (U54 AI117804) is part of the Rare Disease Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), and is funded through a collaboration between NIAID, the National Institute of Diabetes and Digestive and Kidney Diseases, and NCATS and funded in part by the Division of Intramural Research, NIAID. CEGIR is also supported by patient advocacy groups including the American Partnership for Eosinophilic Disorders, Campaign Urging Research for Eosinophilic Diseases, and Eosinophilic Family Coalition. As a member of the Rare Disease Clinical Research Network, CEGIR is supported by its Data Management and Coordinating Center (grant no. U2CTR002818). Funding support for the Data Management and Coordinating Center is provided by NCATS and the National Institute of Neurological Disorders and Stroke. G.S.H. is supported by a grant from the National Institutes of Health (NIH) (grant no. K23 DK131341). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Disclosure of potential conflict of interest: M. E. Rothenberg is a consultant for Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Allakos, Celldex, Nexstone One, Santa Ana Bio, EnZen Therapeutics, Bristol Myers Squibb, AstraZeneca, Pfizer, GlaxoSmithKline, Regeneron/Sanofi, Revolo Biotherapeutics, and Guidepoint and has an equity interest in the first 9 listed; receives royalties from Teva Pharmaceuticals (reslizumab), Mapi Research Trust (PEESSv2.0), and UpToDate; and is an inventor of patents owned by Cincinnati Children’s Hospital. J. M. Spergel is a consultant for ReadySetfood, Regeneron/Sanofi, and ARS Pharma; has grant support from Novartis, Regeneron/Sanofi, Bristol Myers Squibb, Food Allergy Research and Education (FARE), and NIH; receives royalties from UpToDate; and serves on the Data Safety and Monitoring Board for Alladapt and NIAID. M. H. Collins is a consultant for Allakos, Arena/Pfizer, AstraZeneca, Calypso Biotech, EsoCap Biotech, GlaxoSmithKline, Receptos/Celgene/Bristol Myers Squibb, Regeneron Pharmaceuticals, Robarts Clinical Trials, Inc/Alimentiv, Inc, and Shire/Takeda. S. S Aceves is a consultant and an educational speaker for Regeneron/Sanofi; has grant support from the NIH, Campaign Urging Research for Eosinophilic Diseases, Bristol Myers Squibb, and Implicit Biosciences; and is a coinventor of oral viscous budesonide patented by the University of California San Diego and licensed by Takeda. M. Pletneva is a consultant for Allakos. S. K. Gupta is a consultant and/or Data Safety and Monitoring Board member for Adare, Bristol Myers Squibb, QOL, Takeda, Medscape, PVI, ViaSkin, and UpToDate; and receives research support from Allakos, Ellodi, and AstraZeneca. J. B. Wechsler is a consultant for Bristol Myers Squibb, Ellodi, AstraZeneca, Allakos, and Regeneron/Sanofi; and receives research support from Regeneron. N. Gonsalves is a consultant for AstraZeneca, Allakos, Sanofi/Regeneron, AbbVie, Knopp, and Bristol Myers Squibb; is on the speaker bureau for Sanofi/Regeneron; and receives publication royalties from UpToDate. G. W. Falk is a consultant for Allakos, Bristol Myers Squibb/Celgene, Adare/Ellodi, Nexstone, Upstream Bio, and Sanofi/Regeneron; and receives research support from Allakos, Adare/Ellodi, Bristol Myers Squibb/Celgene, and Regeneron/Sanofi. I. Hirano has received research funding from Adare Pharmaceuticals/Ellodi Pharmaceuticals, Allakos, AstraZeneca, Meritage Pharma, Inc, Receptos/Celgene/Bristol Myers Squibb, Regeneron Pharmaceuticals, and Shire/Takeda; and is a consultant for Adare Pharmaceuticals/Ellodi Pharmaceuticals, Allakos, Arena Pharmaceuticals, Aslan Pharmaceuticals, AstraZeneca, Calyx/Parexel, Celldex Therapeutics, Inc, Dermavant, EsoCap Biotech, Gossamer Bio, Eli Lilly, Nexstone, Meritage Pharma, Inc, Phathom Pharmaceuticals, Receptos/Celgene/Bristol Myers Squibb, Sanofi/Regeneron Pharmaceuticals, and Shire/Takeda. M. Chehade has received consultant fees from Regeneron, Adare/Ellodi, AstraZeneca, Sanofi, Bristol Myers Squibb, Recludix Pharma, Allakos, Shire/Takeda, and Phathom; and has received research support from Regeneron, Allakos, Shire/Takeda, AstraZeneca, Adare/Ellodi, and Danone. C. M. Davis has received grant funding from DBV Technologies, Aimmune Therapeutics, Regeneron Pharmaceuticals, and Allergenis. E. S. Dellon is a consultant for Abbott, AbbVie, Adare/Ellodi, Aimmune, Akesobio, Alfasigma, ALK, Allakos, Amgen, Aqilion, Arena/Pfizer, Aslan, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, Eli Lilly, EsoCap, Eupraxia, Ferring, GlaxoSmithKline, Gossamer Bio, Holoclara, Invea, Knightpoint, Landos, LucidDx, Morphic, Nexstone Immunology, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda, Target RWE, and Upstream Bio; has received research funding from Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, GlaxoSmithKline, Meritage, Miraca, Nutricia, Celgene/Receptos/Bristol Myers Squibb, Regeneron, Revolo, and Shire/Takeda; and has received an educational grant from Allakos, Aqilion, Holoclara, and Invea. G. T. Furuta is Chief Medical Officer for EnteroTrack; and receives research funding from Arena/Pfizer. The rest of the authors declare that they have no relevant conflicts of interest., (Copyright © 2024 American Academy of Allergy, Asthma & Immunology. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
50. Home and school pollutant exposure, respiratory outcomes, and influence of historical redlining.
- Author
-
Jung KH, Argenio KL, Jackson DJ, Miller RL, Perzanowski MS, Rundle AG, Bacharier LB, Busse WW, Cohen RT, Visness CM, Gill MA, Gruchalla RS, Hershey GK, Kado RK, Sherenian MG, Liu AH, Makhija MM, Pillai DK, Rivera-Spoljaric K, Gergen PJ, Altman MC, Sandel MT, Sorkness CA, Kattan M, and Lovinsky-Desir S
- Subjects
- Humans, Child, Female, Male, Adolescent, United States epidemiology, Air Pollution adverse effects, Respiratory Function Tests, Nitrogen Dioxide adverse effects, Asthma epidemiology, Environmental Exposure adverse effects, Particulate Matter adverse effects, Schools, Air Pollutants adverse effects
- Abstract
Background: The discriminatory and racist policy of historical redlining in the United States during the 1930s played a role in perpetuating contemporary environmental health disparities., Objective: Our objectives were to determine associations between home and school pollutant exposure (fine particulate matter [PM
2.5 ], NO2 ) and respiratory outcomes (Composite Asthma Severity Index, lung function) among school-aged children with asthma and examine whether associations differed between children who resided and/or attended school in historically redlined compared to non-redlined neighborhoods., Methods: Children ages 6 to 17 with moderate-to-severe asthma (N = 240) from 9 US cities were included. Combined home and school exposure to PM2.5 and NO2 was calculated based on geospatially assessed monthly averaged outdoor pollutant concentrations. Repeated measures of Composite Asthma Severity Index and lung function were collected., Results: Overall, 37.5% of children resided and/or attended schools in historically redlined neighborhoods. Children in historically redlined neighborhoods had greater exposure to NO2 (median: 15.4 vs 12.1 parts per billion) and closer distance to a highway (median: 0.86 vs 1.23 km), compared to those in non-redlined neighborhoods (P < .01). Overall, PM2.5 was not associated with asthma severity or lung function. However, among children in redlined neighborhoods, higher PM2.5 was associated with worse asthma severity (P < .005). No association was observed between pollutants and lung function or asthma severity among children in non-redlined neighborhoods (P > .005)., Conclusions: Our findings highlight the significance of historical redlining and current environmental health disparities among school-aged children with asthma, specifically, the environmental injustice of PM2.5 exposure and its associations with respiratory health., Competing Interests: Disclosure statement Supported by the National Institutes of Health (NIH-K01HL140216), Robert Wood Johnson Foundation, and Amos Medical Faculty Development Award. This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS), and Department of Health and Human Services under contract numbers 1UM1AI114271-01, UM2AI117870, 5UM1AI114271, NCATS/NIH UL1TR001079, NCATS/NIH 1UL1TR001430, NCATS/NIH UL1TR001873, NCATS/NIH UL1TR002345, UL1TRG01422, NIH/NCATS Colorado CTSA UL1 TR002535, NCATS/NIH UL1TR001876, and NIH/CTSA 5UL1TR001425-03. Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest., (Copyright © 2024 American Academy of Allergy, Asthma & Immunology. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.